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Supervisor: Robert M. Krug 
 
Influenza A virus infection causes a highly contagious annual respiratory 
disease in humans as well as periodic pandemics with higher mortality rates. The 
Krug laboratory has shown that one of the major ways that the influenza virus 
NS1 protein counteracts host antiviral responses is to bind the 30 kDa subunit of 
the cleavage and polyadenylation speci ficity factor (CPSF30) . As a 
consequence, 3’ end processing of cellular pre-mRNAis is inhibited, leading to 
reduced production of cellular mRNAs, including interferon mRNAs. I showed 
that NS1-CPSF30 complexes contain an array of cellular proteins. I purified the 
NS1-CPSF30 complexes from virus infected cells by affinity selection of CPSF30 
and the NS1 protein. I identified the associated cellular proteins by mass 
spectrometry. Two cellular RNA helicases, DDX21 and DHX30, were identified. 
SiRNA knockdown of either RNA helicase enhanced virus replication, indicating 
that DDX21 and DHX30 inhibit influenza A virus replication. Further study 
 vii 
demonstrated that DDX21 RNA helicase inhibits viral RNA synthesis, and is 
countered by the NS1 protein. The cellular ZAPL antiviral protein was also 
identified in the NS1-CPSF30 complexes. Previous studies have shown that 
ZAPL antiviral activity is mediated by its N-terminal zinc-fingers, which targets 
viral mRNA of several viruses for degradation. Little is known about the antiviral 
role of the ZAPL C-terminal PARP domain. Here I discovered the antiviral role of 
ZAPL C-terminal PARP domain against influenza A virus. I showed that the 
ZAPL PARP domain targets the viral polymerase PA and PB2 proteins. These 
two viral polymerases are poly(ADP-ribosylated), presumably by other PARP 
protein(s). The ZAPL-associated, poly(ADP-ribosylated) PA and PB2 are then 
ubiquitinated and proteasomally degraded. This ZAPL antiviral activity is 
counteracted by the binding of polymerase PB1 protein to the WWE region 
adjacent to the PARP domain, and causes PA and PB2 to dissociate from ZAPL 
and thus escape degradation. Because PB1 displaces PA and PB2 and protects 
them from ZAPL-mediated degradation, endogenous ZAPL only moderately 
inhibits influenza A virus replication (20-30-fold), as determined by siRNA 
knockdown experiment. These results suggest that influenza A virus has partially 
won the battle against the newly identi fied ZAPL antiviral  activi ty. 
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Chapter 1: Introduction of influenza virus 
1.1 Influenza virus 
1.1.1 Overview 
Influenza, commonly known as “the Flu”, is a highly contagious 
respiratory disease in human, which is caused by influenza virus. Annual 
influenza epidemics cause 3 to 5 million cases of severe illness and about 
250000 to 500000 death each year (World Health Organization, 2014). Larger 
influenza outbreaks in a worldwide range, or pandemics, are less frequent 
throughout human history. There were three major human pandemics 
occurred last century. Among them, the “Spanish flu” in 1918 was the most 
devastating one which killed more than 30 million people. The other two were 
“Asian flu” in 1957 and “Hong Kong flu” in 1968, which also resulted in high 
mortality rates. Influenza virus can cause pandemics due to its capability of 
gene reassortments between different strains, a process known as “antigenic 
shift”. The gene reassortments generate new influenza virus strain which is 
different from previous circulating strains. The little immunological protection 
against these new strains contributes to high mortality rates in human. The 
recent outbreaks of highly virulent avian influenza H5N1 and H7N9 have 
alerted people of the potential new pandemic outbreak (Lamb, 2013; Li et al., 
2004). Fortunately, these viruses have been mainly limited to avain-to-human 
transmission, and have not acquired the ability to cause efficient human-to-
human transmission. 
    Influenza virus is a member of the Orthomyxoviridae family, which 
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contains 5 different virus genera: influenza A, influenza B, influenza C, 
Thogoto virus, and Isavirus. These five different virus genera were defined by 
antigenic differences of their nucleoprotein (NP) and the matrix protein (M1). 
The Orthomyxoviridae family is enveloped viruses with single-stranded, 
negative sense segmented RNA genomes. The viruses in this family are 
capable of gene reassortement in the same type of virus due to their 
segmented genome. However, gene reassortment between different virus 
types (for example, influenza A virus and Thogoto virus) has not been 
reported. Influenza A virus causes human pandemics and it can infect a broad 
range of host, including birds, humans, pigs, horses, seals and whales. 
Influenza B virus infects mainly human and causes seasonal outbreaks, but 
not pandemics. Influenza C virus infects human and pigs with rare frequency 
(Lamb and Krug, 2001). 
    Influenza A virus can be further divided into subtypes based on their 
antigenic difference of two surface proteins, hemagglutinin (HA) and 
neuraminidase (NA). There are at least 16 known subtypes of HA (H1-H16) 
and 9 known subtypes of NA (N1-N9), which is used in naming influenza A 
strains (e.g. H1N1, H3N2, H5N1). All influenza A virus subtypes can be found 
in wild aquatic birds, which are natural reservoir of influenza A virus, whereas 
only a small subset can be found in humans. Recent circulating influenza A 
viruses in human are H1N1 and H3N2 strains (Holmes et al., 2005; Zambon, 
2001). 
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Figure 1.1 Schematic diagram of influenza A virion structure. The location 
of viral structural proteins, envelope, and eight RNA gene segments are 
indicated. The PA-X, PB1-F2, and NS1A protein are expressed and found only 
in infected cells, but not in vrions (Modified from (Noah and Krug, 2005)). 
 
 
 
 
 
 
 
PA-X (?), 
PB1-F2, 
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 PA + PA-X 
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1.1.2 Structure of influenza A virus 
    Schematic diagram of influenza A vrion structure is shown in Figure 1.1. 
The influenza A virus genome is comprised of eight viral RNA segments 
(vRNAs), which encode thirteen or fourteen proteins (Krug and Fodor, 2013; 
Wise et al., 2012). The three largest vRNA segments 1~3 encode three viral 
polymerase subunits PA, PB1 and PB2, respectively. Segment 2 also encodes 
PB1-F2 from alternative reading frame, which serves a virulence factor to 
regulate host cell apoptosis (Chen et al., 2001). Segment 3 through ribosomal 
frameshift also encodes another protein, PA-X, to modulate virulence (Jagger 
et al., 2012). Segment 5 encodes NP that coats all eight vRNA segments, 
together with a single copy of the viral polymerase consisting of the PA, PB1 
and PB2 proteins, to form viral ribonucleoprotein (vRNP) complexes. The NP 
protein is a monomer that nonspecifically and repeatedly binds to single-
stranded vRNA every 24 bases. The 5’ and 3’ ends of vRNA form a partially 
double-stranded structure that serves as a ”promoter” for the viral 
polymerases. The three polymerases with NP proteins are required for viral 
genome replication and RNA transcription (Figure 1.2). Segment 4 and 6 
encodes HA and NA, respectively. The HA and NA are glycoproteins that are 
anchored on the viral bilayer phospholipid envelope to form spike-shaped 
outer layer. The HA protein is a homotrimer that binds the sialic acid receptors 
on the cells, which mediates virus-host cell membrane fusion and entry into 
the cell. The NA protein is a homotetramer that helps virus progeny release 
from cells by hydrolyzing sialic acid on receptors. Segment 7 encodes M1 and 
M2 through alternative splicing. The M1 proteins form a layer under the lipid 
envelope and serves structural function inside viral particle. In the infected  
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Figure 1.2 Schematic diagram of influenza A vRNP structure. The 
influenza A viral ribonucleoprotein complex (vRNP) is comprised of three viral 
polymerases PA, PB1 and PB2 (3P), and nucleoprotein NP. The viral (－) 
sense ssRNA forms a hairpin structure with 5’ and 3’ ends forming a supercoil 
structure where 3P binds to. The NP proteins bind nonspecifically along the 
vRNA (Modified from (Nagata et al., 2008)). 
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cells, the M1 mediates the encapsidation of vRNP into the viral envelope, 
which is essential for virus packaging and budding. The M2 homotetramer 
forms an ion channel, which pumps hydrogen ions (H+) into viral particle 
when virus enters into endosome. This step is important for viral vRNP 
uncoating from M1 and later transfer into nucleus. The smallest segment 8 
encodes NS1 and NS2 through alternative splicing. The NS2 protein, also 
known as NEP, functions as a nuclear export protein for vRNP in infected cells. 
It is associated with M1 in viral particles. The NS1 is a multifunctional protein 
that counteracts many host anti-viral responses and regulates other host and 
viral functions (reviewed in (Krug, 2015)). Among all influenza A viral proteins, 
NS1, PB1-F2, and PA-X are non-structural proteins, and known to only be 
present in infected cells. 
1.1.3 Replication of influenza A virus 
    Figure 1.3 shows the schematic diagram of influenza A vrus life cycle in 
cells. The influenza virus particle through its HA proteins bind to sialic acid 
residues on glycoproteins or glycolipid on cell membrane, which induces 
receptor-mediated endocytosis. Following endocytosis, the viral particle is 
internalized and fused with endosome. The M2 ion channels pump hydrogen 
ions into viral particle/endosome and lower the pH, which leads to M1 
dissociation from vRNPs, disruption of endosome and release of vRNPs into 
cytoplasm. The released vRNPs then migrate into nucleus (Martin and 
Helenius, 1991). Viral RNA replication and transcription take place in nucleus. 
The viral genome is negative sense RNA (vRNA), which serves as template 
for positive sense mRNA and cRNA. cRNA is the complimentary copy of  
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Figure 1.3 Schematic diagram of influenza A vrus life cycle in cells. 
Influenza A virus particle binds to sialic acid receptor on cell membrane, which 
leads to endocytosis and internalization into endosome. The vRNPs are then 
released into cytoplasm and migrated into nucleus. The viral genome is 
replicated and viral RNA is transcribed into mRNA by viral polymerase 
complexes in nucleus. The replicated viral genomes are assembled into 
vRNPs and exported into cytoplasm and packaged with other viral proteins on 
cell membrane. Finally, the progeny virion is released from cell membrane by 
budding process (Adapted from (Lamb and Krug, 2001)). 
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Figure 1.4 Transcription and replication of influenza virus genome 
segments. Negative sense viral RNA (vRNA) transcribed into positive sense 
mRNA with 5’ cap and 3’ poly-A tail. vRNA replicates by synthesis of positive 
sense complimentary RNA (cRNA) intermediates first, which then serve as 
template to synthesize vRNA (Adapted from (Krug and Fodor, 2013)) 
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vRNA, which serves as template for further synthesis of vRNA (Figure 1.4). 
Transcription of influenza A vRNA into mRNA is initiated by the “cap-
snatching” mechanism (Figure 1.5). The vRNP contains the trimeric 
polymerase complex that binds to the partially double-stranded panhandle 
structure formed by the conserved 5’ and 3’ end of each vRNA segment 
(Figure 1.2). The viral mRNA synthesis is initiated by a primer “stolen” or 
“snatched” from host, which is a 10- to 13-bases-long capped RNA primer 
from cellular capped pre-mRNA bound by viral polymerase PB2 subunit and 
cleaved by endonuclease activity of the PA subunit (Dias et al., 2009; 
Guilligay et al., 2008; Plotch et al., 1981). A G residue is added to the 3’CA 
end of the capped primer to initiate the mRNA transcription. In addition, the 
PB1 subunit binding to the double-stranded panhandle structure is also 
required for for transcription (Fodor et al., 1994). Transcription elongation is 
catalyzed by the PB1 subunit, which contains the polymerase active site for 
nucleotide addition. The viral mRNA elongates until the polymerase reaches 
the 4-7 uridine (U) sequence located 16-20 nucleotides from the 5’ end of 
vRNA template. Then the polymerase reiteratively copies the U sequence 
(“sutters”), which generates the poly(A) tail for the viral mRNA in a host-
independent process (Poon et al., 1999). The viral mRNAs then are exported 
into cytoplasm for translation. 
    Replication of influenza A vRNA occurs in two stages. In the first stage, 
the (－) sense vRNA is replicated into (＋) sense full-lengh complimentary 
RNA (cRNA). In the second stage, the cRNA serves as a template to 
synthesize the progeny vRNA. Both cRNA and vRNA synthesis are 
10 
 
 
Figure 1.5 Cap-snatching mechanism to initiate viral mRNA synthesis. 
See text for details (Adapted from (Chen and Krug, 2000)) 
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primer-independent (unprimed initiation), which is different from viral mRNA 
synthesis. The detail mechanism for cRNA and vRNA synthesis has not been 
definitely established. The structure of all three polymerase subunits bound 
with viral RNA promoter was not solved until recently. For the unprimed RNA 
replication, the PB1 protein contains an analogous putative priming loop (641-
657aa) to stabilize the priming and incoming NTPs to facilitate unprimed 
initiation of RNA replication (Krug, 2014; Pflug et al., 2014; Reich et al., 2014). 
    Just like the other viruses, the gene expression of influenza virus is 
regulated during the infection. Immediately after the vRNA transportation into 
nucleus, all eight viral mRNAs are synthesized, and the vRNA, mRNA 
synthesis and protein synthesis are coupled. Afterwards, the infection can be 
divided into early and late stages. In general, the rate of both vRNA and 
mRNA synthesis increase and reach maximal during early stage; however, the 
mRNA synthesis rate is reduced dramatically during late stage, whereas the 
vRNA synthesis remains at similar maximal rate. The viral protein synthesis 
rate continues at maximal levels through the course of infection. To be specific, 
the vRNA, mRNA and protein synthesis of regulatory proteins NP and NS1 
are preferentially occurred during early stage probably because NP regulates 
viral replication and transcription whereas NS1 regulates viral and host gene 
expressions required for viral replication. In contrast, the mRNA and protein 
synthesis of the structural proteins HA, NA and M1 preferentially occur during 
the late stage for the package of progeny viruses (Shapiro and Krug, 1988). 
    After viral genome replication and viral protein synthesis, the vRNP is 
assembled and exported into cytoplasm, which requires association with M1, 
12 
 
NS2/NEP (nuclear export protein) and cellular Crm1 export machinery 
(Akarsu et al., 2003). In the end of the viral life cycle, the vRNP is packaged 
with other viral proteins such as HA, NA, and M2 which are translated and 
transported through Golgi apparatus to the cell membrane. Finally, the 
progeny virion is released from cell membrane by the budding process (Figure 
1.3). 
1.1.4 Polymerase proteins of influenza A virus 
    The influenza A viral polymerase complex is consist of three subunits, PA 
(polymerase acidic), PB1 (polymerase basic 1) and PB2 (polymerase basic 2), 
which binds to the panhandle structure formed by the 5’ and 3’ end of each 
vRNA (Figure 1.2). 
    Figure 1.6 shows two domains of PA identified by proteolytic cleavage 
(Guu et al., 2008; Hara et al., 2006). The N-terminal domain of PA contains 
the endonuclease activity which cleaves the cellular capped pre-mRNA to 
generate a capped primer used for viral mRNA synthesis (the “cap-snatching” 
mechanism). Co-crystallization of PA C-terminal region interacting with N-
terminus of PB1 was solved independently by two groups (He et al., 2008b; 
Obayashi et al., 2008). The structure of PA C-terminal region resembles the 
dragon head and its mouth clamps the small PB1 N-terminal region (Figure 
1.6). Such interaction interface provides clues to the development of new 
antiviral drugs. In addition, the C-terminal region of PA contains a very basic 
groove that could interact with RNA, which is important in viral replication 
(Fodor et al., 2003). The PB1 contains the RNA dependent RNA polymerase 
(RdRp) domain and serves as the core polymerase in the trimeric polymerase  
13 
 
 
Figure 1.6 Diagram of influenza A viral polymerases PA, PB1, PB2, and 
their intersubunit interactions. Three polymerase proteins are shown as bar 
with N- and C-terminal region and functional domains are indicated. The 
regions with known structure are underlined and the corresponding structures 
are shown. The domains involved in intersubunit interactions are connected 
by dotted lines and the co-structures are presented (Adapted from (Resa-
Infante et al., 2011)). 
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complex. In addition, the PB1 binding to the double-stranded panhandle 
structure of vRNA is required for transcription initiation (Fodor et al., 1994). 
PB1 N-terminal region 1-15 amino acids can interact with PA C-terminal 
domain. PB1 via its C-terminal 678-757 aa can also interact with the PB2 N-
terminal region. The PB2 binds to the 5’ cap of cellular capped pre-mRNA, 
which is required for viral mRNA transcription (Blaas et al., 1982; Ulmanen et 
al., 1981). It is important to understand how avian influenza virus adapts to 
human host. Few mutations on certain viral proteins could change host 
specificity. Some mutations are associated with the viral polymerase complex. 
One of the most well-known examples is the mutation of PB2 E to K at 
position 627 renders the avian influenza virus capable of replication in 
humans (Subbarao et al., 1993). However, the functional mechanism is not 
understood. One hypothesis is that, compared to PB2 with E627, the PB2 with 
K627 supports better viral replication in mammalian cells at lower temperature 
(33°C), which is the temperature of human upper respiratory tract; whereas 
the avian PB2 with E627 supports viral replication in birds intestinal tract with 
higher temperature (38–41°C) (Massin et al., 2001). 
    Recently, the Cusack research group just solved the crystal structures of 
complete bat influenza A polymerase complex and human influenza B 
polymerase complex, which contains vRNA promoter bound in both 
complexes (Pflug et al., 2014; Reich et al., 2014). Based on the complete 
crystal structure and by comparing with other known viral RNA polymerase 
structures, Cusack group proposed the structural mechanism by which 
influenza polymerases perform cap-snatching for transcription and unprimed 
initiation for replication, which was commented by Krug in the same issue  
15 
 
 
Figure 1.7 Diagram of RNA transcription by influenza polymerase. See 
text for details (Adapted from (Krug, 2014)). 
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(Krug, 2014). The polymerase proteins forms a U-shaped complex, in which 
PB1 locates in the bottom, and PA endonuclease domain and PB2 cap-
binding domain locate in the two arms, as diagramed in Figure 1.7. Between 
the two arms of U-shaped complex there forms a channel with breadth 
corresponds to the length of the capped RNA primer that is cleaved by PA 
endonuclease from cellular pre-mRNA. The PB2 cap-binding domain binds 
cap of RNA primer, after cleavage by PA, the PB2 cap-binding domain rotates 
about 70゜and directs the capped RNA primer to the PB1 catalytic site to 
initiate transcription. All three polymerase proteins are involved in binding two 
ends of viral RNA which is located close to the PB1 catalytic site for RNA 
synthesis. For the unprimed RNA replication, the PB1 protein contains an 
analogous putative priming loop (641-657aa) to stabilize the priming and 
incoming NTPs to facilitate unprimed initiation (Krug, 2014; Pflug et al., 2014; 
Reich et al., 2014). 
All three polymerase proteins are translated in the cytoplasm and 
transported into nucleus for viral RNA replication/transcription. Although all 
three proteins contain nuclear localization signal, and they can interact with 
each other, they are transported in nucleus differently. The PA and PB1 
protein interacts with each other in cytoplasm and transport into nucleus 
together, whereas PB2 protein transports with Hsp90 into nucleus. Finally, 
they form tripartite polymerase complex in nucleus (Deng et al., 2005; Fodor 
and Smith, 2004). 
1.2 Cellular antiviral response against influenza virus 
1.2.1 Antiviral response mediated by interferons 
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    The viral infection triggers immune responses of host cells to counteract 
the viral invasion. The immune responses include the non-specific innate 
immunity and specific adaptive immunity. The innate immunity is the first line 
of antiviral response, where interferons (IFNs) play an essential role (reviewed 
in (Randall and Goodbourn, 2008; Sadler and Williams, 2008). 
    The IFNs are secreted cytokines, which are divided into three types, type 
I, II, and III based on their protein sequence. Type I IFNs is comprised of a 
large group of molecules, but the most well-known molecules are IFN-α and 
IFN-β, which are induced by viral infection. Type II IFNs contains IFN-γ, which 
is secreted from mitogenically activated T cells and natural killer (NK) cells, 
but are not induced directly by viral infection. Type III IFNs comprise three 
IFN-λ molecules, which is also induced by viral infection and shares the 
pathway as IFN-α/β response. 
The most well established model of IFN-α/β-dependent antiviral response 
is through IFN-β. The induction of IFN-α is less well understood. In general, in 
the viral infected cells, the pattern-recognition receptors (PRRs) detect the 
viral nucleic acid such as the dsRNA and activate the signaling leading to 
activation of IFN regulatory factor-3 (IRF-3) and nuclear factor kappa B (NF-
κB) in cytoplasm. The IRF-3 gets phosphorylated and dimerized, which is then 
transported into nucleus. Freed from its inhibitor IκB that is phosphorylated, 
ubiquitinated and degraded, the NF-kB is then transported into nucleus. The 
IRF-3, NF-κB and c-jun/ATF-2 forms complex called enhanceasome on the 
promoter of IFN-β and recruits transcription machinery, leading to transcription 
of IFN-β gene. The IFN-α/β proteins are then secreted and bind to the IFN-α/β 
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heterodimeric receptor (IFNAR1/IFNAR2) on self or the neighboring 
uninfected cells, which activates the JAK (tyrosine kinases associated with the 
receptor)-STAT (transcription factors that are phosphorylated by JAKs) 
signaling, leading to STAT1/2 heterodimer activation and translocation into 
nucleus. The STAT1/2 and IRF-9 form complex and bind to IFN-stimulated 
response element (ISRE) in the promoters of most IFN-stimulated genes 
(ISGs), leading to their transcriptions. The ISG proteins can either directly or 
indirectly counteract invading viruses so that the cells enter the antiviral state 
to prevent further viral replication and spread. The antiviral states against 
different viruses are established from combination of different ISGs. Some 
ISGs encode PRRs or transcription factors to increase IFN production. Some 
ISGs encodes proteins with direct antiviral functions. Some ISGs regulate 
translation arrest, or cell cycle arrest, or apoptosis, or cytoskeleton remodeling 
which is not favorable for viral replication. In addition to activating ISGs, IFN-
α/β can also activate effector immune cells and promote acquired immune 
response. 
1.2.2 Function of influenza A virus NS1 protein (NS1A protein) in 
counteracting antiviral response 
The smallest influenza vRNA segment 8 encodes the nonstructural 
protein 1 (NS1A), and also NS2A protein through splicing. The NS1A and 
NS2A proteins share the same N-terminal 10 amino acids, and the 
subsequent sequence is different because NS2A uses the +1 reading frame 
after the 3’ splicing site. The expression level of NS1A to NS2A is around 10 
to 1 due to inefficient splicing. The NS1A expresses in high level during viral 
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infection, and is not incorporated into virion. NS1A contains two functional 
domains: N-terminal 1 - 73 amino acids is the RNA-binding domain (RBD) and 
C-terminal 85 - 202~237 amino acids is the effector domain (ED). The NS1A 
RBD forms a symmetric homodimer with a unique six-helical chain fold (Chien 
et al., 1997; Liu et al., 1997; Yin et al., 2007), which binds dsRNA with 
relatively low affinity compared to cellular dsRNA-binding proteins (Tian and 
Mathews, 2001). The NS1A ED forms dimers with each monomer consisting 
of seven β-strands and three α-helices, which has several binding sites for 
viral and cellular proteins that are involved in many functions (Zhao et al., 
2010b) (Figure 1.7). 
NS1A is a multifunctional protein that counteracts many host antiviral 
responses and regulates viral and cellular functions. Overall speaking, one 
major function of NS1A is to inhibit the IFN production or to inhibit the IFN-
mediated antiviral response. Previous study showed one function of NS1A 
RBD is to sequester the viral dsRNA away from being recognized by protein 
kinase R (PKR), thus inhibiting the activation of PKR signaling (Lu et al., 1995; 
Nemeroff et al., 1995). However, subsequent studies from our lab have 
elucidated the function of the NS1A RBD by using Influenza A/Udorn/72 virus 
expressing NS1A with R38A mutant that lose dsRNA binding activity. The 
main function of NS1A RBD is to counteract one of IFN-induced antiviral 
responses, the IFN-α/β-induced 2'-5'-oligo (A) synthetase (OAS)/RNase L 
pathway (Min and Krug, 2006). In addition, the PKR activation is inhibited by 
binding to NS1A ED (123-127 aa), but not due to sequestration of dsRNA by 
NS1A RBD. Further, the NS1A RBD is not involved in inhibition of IFN 
production (Li et al., 2006; Min and Krug, 2006; Min et al., 2007). 
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Figure 1.8 The NS1A protein and its interacting partners with 
corresponding binding regions. See text for details (Adapted from (Zhao et 
al., 2010b)). 
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The NS1A ED contains interaction regions for many cellular proteins to 
regulate their functions, which provides favorable environment for viral 
replication: (1) NS1A ED (103,106; 144-188 aa) binds the 30kD subunit of the 
cleavage and polyadenylation specificity factor (CPSF30), which inhibits the 
cellular pre-mRNA 3’-end processing, leading to reduced antiviral gene 
expression (discussed in detail in section 1.2.3) (Chen et al., 1999; Li et al., 
2001; Nemeroff et al., 1998; Noah et al., 2003; Twu et al., 2006); (2) NS1A ED 
(123, 127 aa) binds N-terminal region of PKR to inhibit its activation by viral 
dsRNA, which then inhibits translation (Li et al., 2006; Min et al., 2007); (3) 
NS1A ED (89; 137-142; 164-167 aa) binds to p85β subunit of 
phosphatidylinositol-3-kinase (PI3K), leading to its activation and thus 
inhibiting viral-induced apoptosis (Ehrhardt et al., 2007; Hale et al., 2006; Shin 
et al., 2007); (4) The avian NS1A ED (213-216) binds to Crk/CrkL to promote 
PI3K activation (Heikkinen et al., 2008); (5) The avian NS1A ED (227-230) 
binds to PDZ to regulate virus pathogenicity in mice (Jackson et al., 2008; 
Obenauer et al., 2006); (6) Recently, the NS1A ED from human H3N2 virus 
was shown to have histone-like sequence (histone mimic, 226-229 aa) that 
binds to human PAF1 transcription elongation complex (hPAF1C) to suppress 
certain antiviral response (Marazzi et al., 2012). It should be noted that these 
NS1A interactions can be virus strain-specific. 
    In addition to the interactions described above, it has been proposed that 
NS1A interacts with retinoic acid-inducible gene I (RIG-I), a critical 
cytoplasmic viral RNA sensor, to inhibit the IFN production (Guo et al., 2007b; 
Mibayashi et al., 2007; Opitz et al., 2007; Pichlmair et al., 2006). RIG-I serves 
as a PRRs to recognize 5’-tri-phosphate on the dsRNA panhandle structure 
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from influenza vRNA, leading to RIG-I activation and interaction with the 
adaptor MAVS, which then serves as a platform to activate the IRF3 and 
NFκB pathway (Takeuchi and Akira, 2009). However, the NS1A binding to 
RIG-I to inhibit IRF-3 activation and IFN production is somewhat controversial 
because it is only established using laboratory-adapted influenza strain 
PR/8/34 (Krug, 2015). 
1.2.3 NS1A protein binds to CPSF30 to block 3’ end processing of 
cellular pre-mRNA 
    One major function of NS1A is to inhibit the IFN production. The NS1A 
through ED interacts with two cellular proteins, CPSF30 (Nemeroff et al., 1998) 
and poly(A)-binding protein II (PABII) (Chen et al., 1999) that are essential for 
cellular pre-mRNA 3’-end processing, to inhibit antiviral gene expression, 
including IFN production. The mechanism by which NS1A binds to CPSF30 
and PABII to block 3’ end processing of cellular pre-mRNA is in Figure 1.8 
(Chen and Krug, 2000). CPSF30 binding site locates on a region centered at 
aa 186, whereas PABII binds to aa 223-237 on NS1A (Li et al., 2001). In 
cellular pre-mRNA 3’end processing, the binding of CPSF complex to the 
AAUAAA poly (A) signal is required for cleavage and polyadenylation of 
cellular pre-mRNAs (Colgan and Manley, 1997). The PABII stimulates the poly 
(A) polymerase (PAP)-catalyzed poly(A) tail synthesis (Chen et al., 1999). 
Therefore, the binding of NS1A to CPSF30 and PABII blocks their function in 
pre-mRNA 3’end processing, which results in accumulation of pre-mRNA with 
short poly(A) tail (~12 nts) in nucleus in influenza infected cells 
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Figure 1.9 Mechanism by which NS1A binds to CPSF30 and PPABII to 
block 3’ end processing of cellular pre-mRNA. See text for details 
(Adapted from (Chen and Krug, 2000)). 
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(Nemeroff et al., 1998). Further, the 5’cap of these accumulated pre-mRNAs 
in nucleus can be cleaved by viral polymerase and used for primer in viral 
mRNA synthesis (the “cap-snatch” mechanism). The inhibition of pre-mRNA 
3’end processing does not affect viral mRNA maturation because the 3’poly(A) 
tail is added to viral mRNA by reiterative copying the U track in the virion RNA 
(Poon et al., 1999). 
    To sum up, there are two main mechanisms by which influenza A NS1 
can inhibit IFN production: (1) to inhibit the RIG-I mediated IRF-3 and NFκB 
activation, thus blocking the IFN gene transcription; and (2) to bind to 
CPSF30/PABII, which inhibits the 3’end processing of IFN pre-mRNA. 
However, whether influenza virus requires both mechanisms to efficiently 
inhibit IFN production is controversial. The observation from our lab that only 
some influenza strains strongly inhibit IRF-3 activation and not all NS1A can 
bind CPSF30 to block pre-mRNA 3’end processing provides some clues. 
Specifically, NS1A from some seasonal H1N1, 2009 pandemic H1N1, and 
H5N1 can strongly inhibit IRF-3 activation, whereas NS1A from seasonal 
H3N2, H2N2, and some seasonal H1N1 does not inhibit IRF-3 activation. The 
NS1A of H3N2 and H2N2, which does not inhibit IRF-3 activation, can bind to 
CPSF30 and inhibit IFN pre-mRNA effectively (Kuo et al., 2010). In contrast, 
the NS1A from 2009 pandemic H1N1 that strongly inhibits IRF-3 activation 
does not bind to CPSF30 effectively (Figure 1.9). However, not all influenza 
viral strains fall into these two categories. For example, the NS1A from H5N1 
after 1997 inhibits both IRF-3 activation and INF pre-mRNA 3’end processing. 
It remains a mystery why one mechanism is sufficient for some viruses 
whereas some viruses require both (Krug, 2015). 
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Figure 1.10 Two main mechanisms by which NS1A inhibit IFN production. 
For some influenza strains, their NS1A either blocks IRF-3 activation or blocks 
pre-mRNA 3’end processing to inhibit IFN production (Adapted from (Krug, 
2015)). 
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Chapter 2: Identify the cellular proteins associated with infected cell 
NS1A-CPSF30 protein complexes 
2.1 Introduction 
    Our lab established that NS1A binds to CPSF30 to block the cellular pre-
mRNA 3’end processing. However, the ability of NS1A to bind CPSF30 is 
virus strain specific. The NS1A from 1997 Hong Kong H5N1 (HK97) does not 
bind to CPSF30 effectively in vitro because two hydrophobic amino acids 
F103 and M106 that are required for stabilization of NS1A-CPSF30 complex 
are mutated to L103 and I106. However, HK97-NS1A binds to CPSF30 to a 
significant extend in vivo because cognate internal viral protein(s) stabilize the 
NS1A-CPSF30 complex in infected cells (Twu et al., 2007). Subsequent study 
showed that viral polymerase complex (PA, PB1, PB2 and NP) serves as the 
cognate proteins to stabilize the NS1A-CPSf30 complexes. Further, the viral 
polymerase proteins were shown to be the integral component of the NS1A-
CPSF30 complex even when the NS1A contains the F103 and M106 and thus 
can bind to CPSF30 effectively (Kuo and Krug, 2009). The study from Kuo et 
al. provided a useful platform to purify the functional NS1A-CPSF30 
complexes from virus infected cells by affinity selectin of CPSF30 and found 
the association of viral polymerase proteins. 
In this study, we further modified the purification procedure from study by 
Kuo et al., 2009 and purified CPSF30-NS1A complexes by sequential affinity 
selection of CPSF30 and NS1A from Influenza A/Udorn/72 virus (Ud) infected 
cells. Then the purified products were subjected to mass spectrometry 
analysis to identify the component proteins. Many host proteins were 
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identified. Several of them belong to the cellular RNA helicase family. We 
tested whether they have functional impact on influenza virus replication by 
knocking down each candidate protein with corresponding siRNA individually. 
Interestingly, knockdown of two RNA helicases (DDX21 and DHX30) out of 
four candidate RNA helicases (the other two are DHX9 and MOV10) 
enhanced viral replication, indicating that DDX21 and DHX30 restrict influenza 
virus replication.  
Further experiments on DDX21 demonstrated that DDX21suppresses 
viral RNA synthesis at early time point of infection due to the ability of DDX21 
binding to PB1, which inhibits assembly of the tripartite viral polymerase (PA, 
PB1 and PB2). At late time point of infection, the increasing amount of NS1A 
binds to DDX21 and displaces PB1 from DDX21, which counteracts the 
DDX21-mediated antiviral activity (Chen et al., 2014). These results 
demonstrated that identification of associated host proteins from purified 
CSPF30-NS1A complexes from infected cells provides a useful platform 
leading to discovery of important host proteins that regulate influenza virus 
replication. 
Two types of anti-influenza drugs are currently available, which targets 
either NA (oseltamivir, zanamivir) or M2 (amantadine/rimantadine) (Das et al., 
2010). However, most circulating influenza A viruses are resistant to 
amantadine/rimantadine and are developing resistance to oseltamivir (Deyde 
2007, Bloom 2010). Thus the development of new anti-influenza drugs is 
required. The present study provides a way to identify associated host 
proteins that play important functions in influenza virus replication. One 
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approach for new antivirals development would be to target these host 
proteins and/or their interaction with specific viral proteins. 
2.2 Materials and Methods 
2.2.1 Cell-lines and recombinant viruses 
HEK-293T human kidney cell-line (ATCC CRL-11268), HeLa human 
cervix adenocarcinoma cell-line (ATCC CCL-2), A549 human lung carcinoma 
cell-line (ATCC CCL-185), Madin-Darby canine kidney cell-line (MDCK) 
(ATCC CCL-34), and Calu3 human lung adenocarcinoma cell-line (ATCC 
HTB-55) were purchased from ATCC. 293T, HeLa, A549 and MDCK cells 
were grown in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO), 2 
mM l-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin (1% PSG) 
(GIBCO) at 37°C under a 5% CO2/95% air atmosphere. Calu3 cells were 
grown in Advanced MEM (GIBCO) supplemented with 10% FBS and 1% PSG 
at 37°C under a 5% CO2/95% air atmosphere. 
H3N2 Inﬂuenza A/Udorn/72 (Ud) virus stocks were grown in 10-day 
fertilized eggs, and virus titers were determined by plaque assays in MDCK 
cells. Recombinant inﬂuenza A viruses were generated using 12 plasmids 
based reverse genetics (Figure 2.1) (Takeda et al., 2002). The negative-
strand viral genomic RNAs are encoded in eight pHH21 plasmids under the 
control of a polymerase I promoter. Eight pHH21 plasmids containing full-
length cDNA for each vRNAs of Ud virus, and four pcDNA plasmid expressing 
PA, PB1, PB2 and NP were provided by Makoto Takeda (Dr. Lamb’s lab, 
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Figure 2.1 The procedure of generating recombinant influenza A Ud 
viruses by 12 plasmids based reverse genetics. See text for details 
(Adapted from (Neumann and Kawaoka, 2001)). 
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Northwestern University). In brief, recombinant Ud virus was generated by co-
transfection of 8 pHH21 plus 4 pcDNA plasmids into 293T cells in serum- and 
antibiotics-free Opti-MEM I medium (GIBCO). Medium was changed to Opti-
MEM I supplemented with 2.5µg/ml N-acetylated-trypsin (Sigma) and 1% 
PSG at 8 hours post transfection. The 293T cells were overlaid onto MDCK 
cells for viral amplification at 18 hours after medium change. If the 
recombinant viruses are generated, the cells will show cytopathic effect (CPE), 
which leads to cell death. Then the supernatant containing the recombinant 
viruses was collected and stored at -80°C. Plaque assay in MDCK cells was 
performed to isolate individual viral plaques. Individual viral plaque was picked 
and injected into the allantoic cavity of 10-day fertilized chicken eggs for 
further virus amplification (Charles River Laboratories) at 34°C. Allantoic fluid 
containing virus was harvested at 48 hours after injection, and stored at -80°C. 
Virus titer (plaque forming units (PFU) /ml) was determined by plaque assays 
in MDCK cells. The viral genomic RNAs were extracted by Trizol reagent 
(Invitrogen) and chloroform method and subjected to RT-PCR using specific 
primers. The cDNAs of each viral RNAs were sequenced for confirmation. 
To generate Ud viruses expressing 1xFLAG-tagged NS1A proteins, a 
FLAG sequence was inserted between the 5’UTR and coding sequence of NS 
reading frame in the pHH21 plasmid by standard cloning procedure. All eight 
genomic RNA segments of the recombinant viruses were sequenced (Zhao et 
al., 2010a). 
2.2.2 Purification of NS1A-CPSF30 complexes from infected cells 
To purify the NS1A-CPSF30 protein complex by sequential affinity 
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selection of CPSF30 and NS1A from Ud infected cells, 4x107 of 293T cells (2x 
150mm dishes) were transfected with a pcDNA3 plasmid encoding N-terminal 
glutathione S-transferase (GST) tagged CPSF30 (GST-CPSF30) using the 
Mirius TransIT-LTR Transfection reagent (Kuo and Krug, 2009), and 24 hours 
later were infected with 2 plaque-forming units/cell of either wild-type Ud virus 
or the Ud virus expressing a 1xFlag-tagged NS1 protein (Zhao et al., 2010a). 
Cells were collected 12 hours after infection, and were disrupted by 
suspension in a lysis buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 
5 mM EDTA, 2.5 mM MgCl2, 1% NP40, 10% glycerol, 1 mM PMSF, and 1x 
Protease inhibitor (Roche), followed by passage through a 25 gauge needle 
several times for further disruption. The extracts were diluted with a buffer 
containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM PMSF, and 1x 
Protease inhibitor to make the 0.5% final concentration of NP40, and affinity 
purified using glutathione sepharose beads (Amersham). The glutathione 
sepharose beads that bound to GST-CPSF30 complexes were washed in a 
solution containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.5% NP40, 
and eluted by 10mM glutathione. The eluate was then bound to agarose 
beads conjugated with the M2 monoclonal Flag antibody (Sigma), washed 
four times with a buffer containing 50 mM Tris-HCl pH7.5, 150 mM NaCl, 
0.25% NP40, and Flag-NS1A containing protein complexes were eluted with 
500 ng/ml of 3xFlag peptides (Sigma). Immunoblots confirmed that the 
purified product contains GST-CPSF30 and 1xFlag-NS1A (Chen et al., 2014). 
2.2.3 Mass spectrometry analysis of the purified NS1A-CPSF30 
complexes 
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    The purified product was then concentrated using Amicon centrifugal filter 
units with 10kD cut-offs (Millipore). An aliquot of the concentrated purified 
product was analyzed by SDS-PAGE gel, which was stained with colloidal 
blue (Invitrogen) to visualize the purified proteins. Gels from several molecular 
weight regions were cut out and sent for mass spectroscopy analysis by 
Harvard Taplin Mass Spectrometry Facility. Another aliquot of the 
concentrated purified product was analyzed by immunoblots probed with the 
indicated antibodies. Repeated rounds of purification and mass spectrometry 
have been done and the identified proteins associated with GST-CPSF30 and 
1xFlag-NS1A complexes were very consistent (Chen et al., 2014). 
2.2.4 SiRNA knockdown of DDX21 or DHX30 
    Four RNA helicases were identified associated with the GST-CPSF30 
and 1xFlag-NS1A complexes. Knockdown of each helicases by corresponding 
siRNA was performed to screen whether they have functional impact on 
influenza virus replication in cells. All siRNA duplexes were designed and 
synthesized by Invitrogen (Stealth RNAi™ siRNA), and re-suspended in 
DEPC-treated water to a final concentration of 20µM for storage at -80°C. 
SiRNA sequences used in this study (chapter 2) are shown in Table 2.1.  
For preliminary screening, three siRNAs from Invitrogen were mixed and 
tested for knockdown efficiency of target gene in HeLa cells. To further test 
functional impact of candidate genes on influenza virus replication, siRNA 
knockdowns were performed in HeLa cells followed by infection of Ud virus at 
2-5 pfu/cell for detection of viral protein synthesis in single cycle of viral 
growth.  
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Table 2.1 siRNA sequences used in this study 
Target      Oligo#         Sequence (complimentary sequence not shown) 
DDX21       1          5’- CCA GCG CUC CUU GAU CAA CUC AAA U 
DDX21       2          5’- GCU GGG CGA GGA GAU UGA UUC CAA A 
DHX30       1          5’- CAA GGU GAU UCA GAU UGC AAC GUC A 
DHX30       2          5’- GCG GCA GCU GAA UCC AGA GAG UAU U 
Control                  5’- UUG AUG UUG AGC AAU UCA CGU UCA U 
Table 2.2 Primer sequences used in this study 
Target       Strand        Sequence 
DDX21      Forward      5’- CCA GCA AAG ATG CCA TCA GGC TTT 
DDX21      Reverse      5’- CCA GCG TCG TGA ATC ATG CCA TTT 
DHX30      Forward      5’- AAT GCG CAC TCG ATT TGG ACC TTG 
DHX30      Reverse      5’- GCT GTC ATG GCT CAA CAG TGC TTT 
DHX9       Forward      5’- TCG AGC CAT CTC TGC TAA AGG CAT 
DHX9       Reverse      5’- TTC CAT TGT CGT ATC GGG CCA TCT 
MOV10      Forward      5’- GGC AAT TAA GCA GGT GGT GAA GCA 
MOV10      Reverse      5’- AAG CGT TCT CGA TCC ACG ACA TCA 
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The candidate genes that had effect on viral protein synthesis in single cycle 
growth were then tested for their effect in Calu-3 cells with siRNA knockdown 
followed by Ud virus infection at 0.001 pfu/cell for analysis of infectious virus 
produced in multiple cycle of viral growth. 
To perform siRNA knockdown in HeLa cells, the Xtreme ®  siRNA 
transfection reagent (Roche) was diluted in Opti-MEM I (Invitrogen) for 5 
minutes, whereas the siRNA was diluted in Opti-MEM I and then mixed with 
the diluted transfection reagent in a ratio of 2.5µl reagent per 20nM final 
concentration of siRNA in cell culture. The siRNA mixture was incubated for 
another 20 minutes before gently added into cell culture that have been 
changed with fresh DMEM containing 10% FBS and 1% PSG. 20nM final 
concentration of siRNA was used for knockdown in HeLa cells for 36 - 48 
hours before virus infection. For maximal knockdown efficiency in Calu-3 cells, 
cells were trypsinized, washed and re-suspended in serum- and antibiotics-
free Advanced MEM. At 8 - 18 hours after addition of siRNA mixture into re-
suspended Calu-3 cell cultures, medium was replaced with fresh Advanced 
MEM with 10% FBS and 1% PSG. 80 - 100nM final concentration of siRNA 
was used for knockdown in Calu-3 cells for 36 - 48 hours before virus 
infection. 
2.2.5 RNA Extraction and Semi-quantitative Reverse Transcription (RT)-
PCR 
    For preliminary screening the siRNA knockdown efficiency, mRNA level of 
target genes (DDX21, DHX30, DHX9 and MOV10) were determined. Cells 
transfected with siRNA against each target for 36-48 hours were extracted 
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and total RNA was extracted with the Trizol reagent (Invitrogen) and 
chloroform according to manufacturer’s instructions. A mixture of the RNA and 
the oligo-dT primer was incubated at 65°C for 10 minutes, and then added to 
the reverse transcription mixture containing reverse transcriptase (Roche), 
dNTP, and RNaseOut (Invitrogen). After incubation at 55°C for 30 minutes, the 
generated cDNA was PCR amplified using PCR supermix (Invitrogen) with 
specific primers for each candidate target genes (Table 2.2). Amplified PCR 
products were separated by electrophoresis on 1% agarose. 
2.2.6 Antibodies and Immunoblotting 
Antibody against the major structural proteins of Ud virus, which detects 
NP as well as HA and M1, was provided by Robert A. Lamb (Chen et al., 
2007). NS1 antibody was generated against GST tagged NS1A protein from 
our lab. Actin and tubulin antibodies were obtained from Sigma and Cell 
Signaling, respectively. DDX21 and DHX30 antibodies were obtained from 
Abcam. 
Cells harvested at indicated time were extracted in a lysis buffer 
containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 2.5 mM 
MgCl2, 1% NP40, 10% glycerol, 1 mM PMSF, and 1x Protease inhibitor 
(Roche). Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membrane (Bio-Rad) by semi-dry transfer method. Membrane 
was blocked in TBS containing 0.2% Tween (TBST) and 5% non-fat milk, and 
then incubated with the primary antibody against the protein of interest. After 
washing away unbound primary antibody with TBST, the membrane was 
incubated with the corresponding secondary antibody. After another wash with 
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TBST, proteins on the membrane were detected with enhanced 
chemiluminescence (ECL) western blotting substrate (Pierce) and exposed to 
CL-Xposure film (Pierce). 
2.2.7 Virus infection and plaque assays 
    For single cycle virus replication, HeLa cells were infected with Ud virus 
at 2-5 pfu/cell (high multiplicity of infection or high M.O.I.). HeLa cells were 
washed with PBS to remove serum in the medium. Ud virus was diluted in 
serum-free DMEM containing 1% BSA and 1% PSG, and added onto cells at 
2-5 pfu/cell. Cells were incubated at 37°C for 1 hour to let virus binds to cells. 
After wash with PBS and change with fresh serum-free DMEM and 1% PSG, 
cells were incubated for the indicated times. For multiple cycle virus 
replications, Calu-3 cells were infected with Ud virus at 0.001 pfu/cell (low 
M.O.I.). Calu-3 cells were washed and incubated with diluted Ud virus in 
serum-free Opti-MEM I containing 1% BSA and 1% PSG. After 1 hour 
incubation, cells were washed with PBS and replaced with Advance MEM 
containing 2.5µg/ml N-acetylated trypsin and 1% PSG. At indicated time post 
infection (usually 12, 24, 36 and 48 hours), small amount of supernatant from 
cell culture was harvested and the virus titer was determined by plaque 
assays. 
    For plaque assays, confluent monolayer MDCK cells were washed and 
infected with serial 10-fold dilutions of virus in serum-free DMEM containing 
1% BSA and 1% PSG. After 1 hour virus absorption, medium was replaced 
with serum-free DMEM containing 1% PSG and 2.5µg/ml N-acetylated trypsin 
pre-mixed with 1% (final conc.) non-solidified agarose at 42°C. The solidified 
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cell culture was incubated for 48 hours and formation of viral plaques against 
viable cells was stained and visualized with crystal violet. 
2.3 Results 
2.3.1 Purification of NS1A-CPSF30 complexes from influenza A virus 
infected cells 
    The basic experimental procedure for purification of NS1A-CPSF30 
complexes from influenza virus infected cells is diagrammed on in Figure 2.2 
(A). To scale-up the purification to get enough product for mass spectrometry 
analysis, 4x107 of 293T cells (2 x 150mm dishes) were transfected with GST-
CPSF30 for 24 hours, and infected with either wild-typed Ud virus (as a 
control) or Ud virus expressing 1xFlag-NS at 2 pfu/cell. 12 hours after 
infection, cells were collected and extracted. Cell lysate was first selected with 
GST beads to pull down GST-CPSF30-containing protein complexes, which 
was subsequently selected with beads conjugated with anti-Flag M2 antibody 
to immuneprecipitate 1xFlag-NS-containing protein complexes. 
    During the purification procedure, aliquots of each step were analyzed by 
immunoblots to monitor the purification specificity and efficiency (Figure 2.2). 
The immunoblot with antibody against NS1A shows similar expression of wt-
NS1A and 1xFlag-NS1A in cells. After binding to GST beads, there were some 
unbound GST-CPSF30 and 1xFlag-NS1A remaining in the cell lysate (lane 2 
and 3 in Figure 2.2 (B)). Complexes containing GST-CPSF30 and wt-NS1A or 
1xFlag-NS1A were successfully selected and eluted from GST-beads (lane 4 
and 5). Elution efficiency was high because there was not much left in the  
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Figure 2.2 Purification of NS1A-CPSF30 complexes from infected cells. 
(A) 293T cells were transfected with GST-CPSF30 for 24 hours and then 
infected with either wt Ud or Ud expressing 1xFlag-NS. 12 hours after 
infection, cells were collected and extracted for sequential selection with GST 
pull-down followed by Flag immunoprecipitation. (B) Immunoblot of GST pull-
down. Cells infected with wt-Ud (W) or Ud expressing 1xFlag NS (F) were 
selected with GST beads. BB: cell extract before binding to GST-beads; BA: 
cell extract after binding to GST-beads; E1: first elution from GST-beads; E2: 
second elution from GST-beads; Beads: GST-beads after two rounds of 
elution. (C) Immnoblot of Flag selection. Eluate from GST pull-down was 
selected with beads conjugated with Flag M2 antibody. BA: eluate after 
binding to anti-Flag-beads. E1: first elution from anti-Flag-beads; E2: second 
elution from anti-Flag-beads; Beads: anti-Flag-beads after two rounds of 
elution. 
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second elution and on the beads (lane 6 - 9). The eluate from GST beads was 
subsequently selected with anti-Flag M2 beads. After binding to anti-Flag-
beads, the complexes containing GST-CPSF30 and wt-NS1A were still in the 
eluate (lane 1 and 3 in Figure 2.2 (C)), whereas the complexes containing 
GST-CPSF30 and 1xFlag-NS1A were effectively selected and eluted from 
anti-Flag-beads, indicating the high specificity and efficiency of Flag selection 
(lane 2 and 4). Elution efficiency was high because there was not much left in 
the second elution and on the beads (lane 5 - 8) (Chen at al. 2014). 
2.3.2 Identification of the cellular proteins associated with the NS1A-
CPSF30 complexes by mass spectrometry 
    The purified complexes containing CPSF30 and NS1A were 
immunoblotted with antibody against the known associated viral proteins. The 
immunoblots in Figure 2.3 (A) showed that the purified complexes contain not 
only NS1A and GST-CPSF30, but also viral polymerase proteins PA, PB1, 
PB2 and NP, confirming previous results from our lab (Kuo and Krug, 2009). 
Notably, 1xFlag-NS2A/NEP protein (15 kDa) was not detected, presumably 
because it does not bind to CPSF30 and hence was not co-purified by GST 
pull-down. The purified CPSF30-NS1A product from either wt-NS1 control or 
1xFlag-NS1 sample were resolved by SDS-PAGE electrophoresis, and 
visualized by Colloidal blue staining (Figure 2.3 (B)). Two major bands on gel 
correspond to GST-CPSF30 (~50 kDa) and 1xFlag-NS1A (~27 kDa). The 
Flag-NS1 sample contains proteins larger than 65 kDa that were absent in the 
control wt NS1 sample. Therefore, the gel pieces of region of high molecular 
weight (region of interest, 70 - 170 kDa) were cut out and sent to Harvard for  
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Figure 2.3 The purified NS1A-CPSF30 complexes contains many other 
proteins. (A) Immunoblot for the viral PA, PB1, PB2, NP and NS1 proteins 
and for CPSF30 in the purified CPSF30-NS1A complexes from Flag-NS1 
sample or the control wt NS1 sample (Adapted from (Chen et al., 2014)). (B) 
SDS-PAGE electrophoresis followed by Colloidal blue staining of the proteins 
in the purified CPSF30-NS1A complexes from Flag-NS1 sample or the control 
wt NS1 sample. 
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Table 2.3 Mass spectrometry result of associated proteins in purified 
CPSF30-NS1A complexes 
70-90 kDa 90-110 kDa 110-140 kDa 140-170 kDa 
Protein Matches Protein Matches Protein Matches Protein Matches 
PABP4 10 DDX21 27 DHX9 21 MYH9 20 
HNRPM 10 Nucleolin 27 DHX30 18 CPSF160 18 
PABP3 5 Mov10 23 Matrin3 16 LaRP1 11 
FIP1 5 PB1 14 LaRP1 11 Q65ZQ1 6 
Y00305 3 ZAP 13 Nucleolin 10 DDX21 6 
PB2 3 ILF3 11 HNRPU 8 MYH10 4 
 
CPSF100 8 Q65ZQ1 6 WDR33 3 
Q65ZQ1 6 Rent1 6 O14654 3 
DHX36 6 CL010 6 
 
HNRL1 6 DDX21 5 
HNRPU 4 SF3B3 5 
RBM28 4 Q9Y687 3 
XRN2 4 
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mass spectrometry analysis. Repeated rounds of purification and mass 
spectrometry analysis were done and the results were very consistent. Hence 
only one representative result from mass spectrometry is shown and 
summarized in Table 2.3. Four different regions based on molecular weight 
were analyzed. Number of peptides that matched the protein sequence was 
indicated as “Matches”. Several influenza viral polymerase proteins were 
identified associated with NS1-CPSF30 complexes: PB2 in 70 - 90 kDa region, 
and PB1 in 90 - 110 kDa region, which was consistent with and confirmed the 
immunoblot result. Importantly, several CPSF subunit proteins (FIP1 in 70 - 90 
kDa, CPSF100 in 90 - 110 kDa; CPSF160 in 140 - 170 kDa) and PABP 
proteins (PABP3 and PABP4 in 90 - 110 kDa) were identified, which validated 
our purification procedure and demonstrated that we purified functional active 
NS1-CPSF30 complexes from infected cells (Chen and Krug, 2000). 
    Interestingly, four cellular RNA helicases were identified as top 
candidates associated with NS1-CPSF30 complexes. DDX21 (27 matches) 
and MOV10 (23 matches) were in the 90 - 110 kDa region, and DHX9 (21 
matches) and DHX30 (18 matches) were in the 110 - 140 kDa region. The 
other top candidates were nucleolin (27 matches, 70 - 90 kDa) which is major 
nucleolar protein, and ZAP (13 matches, 70 - 90 kDa) which is a zinc-finger 
antiviral protein (the main project of my thesis, presented in chapter 3), and 
MYH9 (20 matches, 140 - 170 kDa) which is heavy-chain of a non-muscle 
myosin. 
Among the four candidate four RNA helicases, DHX30 was reported to 
have a role in HIV-1 gene expression (Zhou et al., 2008). DHX9 was reported  
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Figure 2.4 siRNA knock down of four candidate RNA helicases and their 
effect on viral replication. (A) Semi-quantitative RT-PCR for the knockdown 
of DHX9, MOV10, DDX21 and DHX30 mRNA by mixture of three siRNA 
(Invitrogen) in HeLa cells, respectively. β-actin mRNA served as an internal 
loading control. (B) Immunoblot for the effect of knocking down each RNA 
helicase on virus replication. HeLa cells were transfected with siRNA against 
each RNA helicase separately for 48 hours, and then infected with Ud virus at 
2 pfu/cell. Cells were collected 6 hours post infection and immunobloted with 
antibody against NS1A, and Ud structural proteins (HA, NP and M). (Done by 
Guifang Chen) 
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to have roles in HCV replication (He et al., 2008a) , and have role in 
promoting HIV-1 replication at both reverse transcription and translation 
stages (Xing et al., 2010). DDX21 was reported to regulate translation of 
polycistronic mRNA of Borna disease virus (Watanabe et al., 2009). MOV10 
was reported to be involved in hepatitis delta virus replication (Haussecker et 
al., 2008). However, no known functions were reported for these four 
candidate RNA helicases in influenza virus replication. We were interested in 
whether these RNA helicases play any role in influenza virus replication. 
2.3.3 SiRNA knocking down of the identified RNA helicases DDX21 or 
DHX30 enhances influenza A virus replication in cells 
    To determine whether the four candidate RNA helicases play roles in 
influenza A virus replication, we knocked down each of them by siRNA and 
determined whether this knockdown impacted Ud virus replication. HeLa cells 
were transfected with a mixture of three siRNAs against each RNA helicase 
for 48 hours, and then infected with Ud virus at high M.O.I. (2 pfu/cell). Cells 
were collected at 6 hours post infection, and viral proteins were measured by 
immunoblot. Figure 2.4 (A) shows that mRNA of each RNA helicase could be 
knocked down by the mixture of siRNA with high efficiency. The measurement 
of viral protein expression in single cycle growth is a good estimate of the 
extent of virus replication. We found that knockdown of DHX9 or MOV10 only 
slightly increased NS1 protein expression, and did not affect protein 
expression of the major structural proteins HA, NP and M1 (Lane 2, 3 
compared to lane 1). However, knockdown of DDX21 or DHX30 significantly 
increased protein expression of NS1, HA, NP and M1, indicating that DDX21  
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Figure 2.5 Knockdown of DDX21 or DHX30 by siRNA significantly 
increases influenza Ud virus replication. (A) Immunoblot for knockdown of 
DDX21 protein by two different siRNA (denoted as 21i-1 and 21i-2). β-actin 
protein served as an internal loading control. (B) Multiple cycle growth curve 
of Ud virus in Calu-3 cells. Calu-3 cells were transfected with siRNA against 
DDX21 (21i-1 or 21i-2) or control siRNA for 36 hours, and then infected with 
Ud virus at 0.001 pfu/cell. Supernatant containing released virus were 
collected at indicated time points post infection and virus yield was 
determined by plaque assay in MDCK cells. (C) Immunoblot for knockdown of 
DHX30 protein by two different siRNA (denoted as 30i-1 and 30i-2). (D) 
Multiple cycle growth curve of Ud virus in Calu-3 cells. Calu-3 cells were 
transfected with siRNA against DHX30 (30i-1 or 30i-2) or control siRNA for 36 
hours, and then infected with Ud virus at 0.001 pfu/cell. (Done by Guifang 
Chen) 
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and DHX30 inhibit influenza virus replication (Lane 4, 5 compared to lane 1). 
    To further confirm that DDX21 and DHX30 inhibit influenza virus 
replication, we performed multiple cycle growth of Ud virus in Calu-3 cells 
which is human airway epithelial cell-line. Calu-3 cells were transfected with 
siRNA against DDX21 or DHX30 for 36 hours (Figure 2.5 (A) and (C)), and 
then infected with Ud virus at low M.O.I (0.001 pfu/cell). At the indicated time 
points post infection, small aliquots of supernatant containing released virus 
were collected and virus yield was determined by plaque assay in MDCK cells. 
Replication of Ud virus was significantly enhanced in either DDX21 or DHX30 
knockdown cells, approximately 30-fold increase compared to control cells for 
DDX21 knockdown (Figure 2.5(B)) and 2-log increase compared to control 
cells for DHX30 (Figure 2.5(D)), demonstrating that DDX21 and DHX30 inhibit 
influenza A virus replication in human cells. Similar results were also obtained 
in HeLa cells and also with different influenza A virus strain (H1N1 influenza 
A/WSN/33) (Chen et al., 2014). 
2.3.4 Mechanism for antiviral activity of DDX21 against influenza A virus 
    Further studies on DDX21 from our lab have revealed the mechanism of 
the antiviral activity of DDX21 against influenza A virus (Chen et al., 2014). 
We showed that DDX21 inhibits influenza A virus replication by binding to PB1 
protein and blocking viral polymerase complex formation, leading to reduced 
viral RNA synthesis and protein expression at early times of infection. At later 
times of infection when sufficient NS1 proteins have been synthesized, the 
DDX21 antiviral activity is counteracted by NS1 protein, which binds to 
DDX21 and displaces PB1 from DDX2. As a consequence, viral polymerase  
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Figure 2.6 Mechanism for DDX21 regulation of influenza A virus RNA 
synthesis. At early times of infection, DDX21 inhibits viral RNA synthesis by 
binding to PB1 protein thus reducing the formation of viral polymerase 
complex. However, at later times of infection when sufficient amount of NS1 
protein have been made, this antiviral activity is counteracted by the NS1 
protein, which binds to DDX21 and displaces PB1 from DDX21. (Modified 
from (Chen et al., 2014)) 
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complex formation is not blocked and viral RNA synthesis is no longer 
inhibited (Figure 2.6). 
    Chen et al. further showed that DDX21 binds to the RNA binding domain 
of the NS1 protein and identified amino acids K41 and R44 were required for 
DDX21 binding. However, K41 and R44 are also involved in binding dsRNA, 
α-importin, and NP (Cheng et al., 2009; Chien et al., 2004; Gack et al., 2009; 
Melen et al., 2007; Robb et al., 2011). To prove the mechanism, a NS1-
K41A/R44A double mutant virus (41/44 virus) was generated. The virus with 
mutant NS1 that cannot bind to DDX21 showed reduced viral protein 
expression at both early and later times of infection. Knockdown of DDX21 
rescued the phenotype of mutant 41/44 virus to that of wild-type virus, 
demonstrating the 41/44 virus was attenuated due to antiviral activity of 
DDX21, but not the other K41/R41-involved-functions. 
2.3.5 Mechanism for antiviral activity of DHX30 against influenza A virus 
    The study of mechanism by which DHX30 inhibits influenza A virus is still 
in progress in our lab. Unpublished data from our lab showed that, just like 
DDX21, DHX30 can inhibit viral RNA synthesis at early times of infection. In 
addition, DHX30 was found to interact with NS1A but not PB1 or the other 
viral polymerases. Interestingly, amino acids K41 and R44 of NS1A are also 
required for DHX30 binding. While DDX21 requires full-length protein to be 
functional, DHX30 N-terminal RNA-binding domain is sufficient to inhibit virus. 
Currently two hypotheses are under tested: (1) DHX30 binds to viral RNA 
directly, which affects viral RNA synthesis; and (2) because region around K41 
and R44 of NS1A is involved in many other functions, DHX30 binding to NS1A 
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may affect NS1A’s function in regulation of viral replication. 
2.4 Discussion 
    Replication of virus in host cells involves the interplay between viral and 
host cellular proteins. One important field for influenza A virus research is to 
identify host proteins that regulate viral replication through interaction with 
specific viral proteins. Our previous findings that NS1A forms complex with 
CPSF30 to block the pre-mRNA 3’ end processing, and that viral polymerase 
proteins are associated with the NS1A-CPSF30 complexes led us to purify 
these macromolecular complexes to determine whether additional cellular 
proteins are associated with these complexes. Our current approach is to 
purify such macromolecular complexes from influenza virus infected cells, and 
identify host proteins that are associated with these complexes, and then 
determine whether the identified host proteins have any role in virus 
replication.  
We modified the purification procedure from single selection of GST-
CPSF30 reported in study by Kuo et al. to sequential selection of GST-
CPSF30 and Flag-NS1A. The only proteins that are present in the purified 
protein complexes should be CPSF30, NS1A and proteins interacting with 
CPSF30 and/or NS1A. The associated cellular proteins could either directly or 
indirectly interact with CPSF30 and/or NS1A. In the present study, we showed 
that the double purification procedure was efficient and specific (Figure 2.2). 
The macromolecular complexes containing CPSF30 and NS1A were purified. 
The presence of not only CPSF30 and NS1, but also viral polymerase protein 
PA, PB1, PB2 and NP was confirmed, which was consistent with our previous 
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results. The NS2A was not found in the purified protein complexes, which 
provides a way to separate NS1A from NS2A in determining interaction 
partners (Figure 2.3). The mass spectrometry analysis of the purified product 
indeed identified many associated proteins, including viral polymerase 
proteins and CPSF subunit proteins that should be present in the protein 
complex, which validated our purification of functional active protein 
complexes from viral infected cells (Table 2.3). In addition, four host RNA 
helicases were identified as top associated proteins on the list, and siRNA 
knockdown screening showed that two out of four, DDX21 and DHX30 inhibit 
virus replication (Figure 2.4 and 2.5). 
We showed that DDX21 RNA helicase that is associated with the 
CPSF30-NS1A complexes is a host factor that regulates viral RNA synthesis 
via interaction with PB1 at early time points and with NS1A at later time points 
(Figure 2.6). The interaction of DDX21 with NS1A explains how DDX21 is 
associated with the CPSF30-NS1A complexes. Interestingly, DDX21 was not 
identified in previous study that aimed to determine the host proteins involved 
in influenza A virus replication by RNAi screening (Watanabe et al., 2010). 
Another study reported that DDX21 interacts with transfected PA-PB1 hetero-
dimer protein in RNase-sensitive manner, suggesting RNA-mediated 
interaction (Bradel-Tretheway et al., 2011). However, our results showed that 
DDX21 binds to PB1 but not PA in RNase-resistant manner, indicating protein-
protein interaction, which emphasizes the validity of identifying specific viral-
host protein interaction from viral infected cells. 
The NS1A protein has binding sites for many cellular proteins, and some 
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of these interactions may be mutually exclusive (Krug and Garcia-Sastre, 
2013). It is very likely that multiple NS1-CPSF30 complexes exist due to 
different cellular protein bound to NS1A. Further, while some NS1-CPSF30 
complexes contain viral polymerase proteins as confirmed by immunoblot and 
mass spectrometry (Figure 2.3, Table 2.3), some of the NS1-CPSF30 
complexes from Ud infected cells probably do not have association of viral 
polymerase proteins because Ud NS1A can stably interact with CPSF30 
without stabilization from cognate viral polymerase proteins (Kuo and Krug, 
2009). The NS1-CPSF30 complexes that interact with DDX21 most likely do 
not contains viral polymerase proteins as integral components, particularly 
because DDX21 binds to only PB1 but not PA and PB2 at early times and 
binds to NS1A at later times of infection. Hence the purified NS1-CPSF30 
complexes containing DDX21 were most likely the complexes formed at later 
time of infection, consistent with the procedure that the infected cells were 
collected at 12 hours post-infection. 
To determine the function of NS1A-DDX21 interaction, Chen et al., 
identified the binding site of DDX21 on NS1A protein, and demonstrated that 
the Ud virus expressing mutant NS1A that cannot bind to DDX21 cannot 
counteract the antiviral activity of DDX21. This result showed that 
endogenous DDX21 inhibits viral RNA synthesis, which is in turn suppressed 
by NS1A in infected cells. Additional proof for antiviral activity of DDX21 would 
be to determine the binding site of DDX21 on PB1 and generated a virus 
expressing mutant PB1 that cannot be targeted by DDX21. Since PB1 
structure was solved recently (Reigh et al., 2014; Pflug et al., 2014), further 
study is needed to determine whether it is feasible to generate such PB1 
52 
 
mutant virus whose primary defect is in DDX21 binding. 
DDX21 probably interacts with PB1 in the cytoplasm before it forms 
complex with PA and being transferred into nucleus for tripartite viral 
polymerase formation (Fodor and Smith, 2004). Although DDX21 is a 
nucleolar protein, studies have shown that DDX21 participates in cytoplasmic 
functions. DDX21 was reported to regulate translation of polycistronic mRNA 
of Borna disease virus (Watanabe et al., 2009); and DDX21 forms complex 
with another two RNA helicases to sense dsRNA in dendritic cells (Zhang et 
al., 2011b). On the other hand, the interaction between DDX21 and PB1 or 
NS1 may interfere with DDX21’s cellular function. DDX21 was recently 
reported to regulate transcription and ribosomal RNA processing (Calo et al., 
2014). It would be interesting to determine whether influenza virus regulates 
cellular transcription and ribosomal RNA processing through binding and 
sequestering DDX21. 
For the anti-influenza viral drugs development, the binding sites of 
DDX21 on NS1A have been determined, which are around the region (R37, 
R38, K41 and R44) also participates in binding dsRNA, α-importin, TRIM25 
and NP (Cheng et al., 2009; Chien et al., 2004; Gack et al., 2009; Melen et al., 
2007; Robb et al., 2011). Since this region on NS1A is crucial for multiple 
functions required for virus replication in cells, inhibitors against this region 
would be expected to strongly inhibit virus replication. Actually, our lab and 
others have been shown that influenza virus expressing NS1 with mutations in 
this region are highly attenuated (Donelan et al., 2003; Gack et al., 2009; Min 
and Krug, 2006). 
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Ch.3 Identification of a novel battle between influenza A virus and a 
newly identified ZAPL antiviral activity 
3.1 Introduction 
    In addition to the four host RNA helicases identified associated with the 
purified CPSF30-NS1A complexes, we surprisingly found the association of 
the host antiviral protein ZAP, which was with 13 matches identified in the 90 - 
110 kDa region (Table 2.3). We were very curious about the presence of an 
antiviral protein in the host-viral complex. 
3.1.1 ZAP is a CCCH-type zinc-finger antiviral protein 
    ZAP is a CCCH-type zinc-finger antiviral protein. There are two dominant 
isoforms of ZAP in human cell: one is a longer 902 amino acids protein 
(denoted as ZAPL) that contains an N-terminal zinc-fingers domain, an 
internal TPH and WWE domains, and a C-terminal PARP-like domain. The 
other one is a shorter 699 amino acids protein (denoted as ZAPS) with 
identical N-terminal and internal domains but lacks the C-terminal PARP-like 
domain of ZAPL (Figure 3.1) (Kerns et al., 2008). By screening the 
mammalian cDNA library for genes that confer antiviral activity, Steven Goff 
Lab has identified that the zinc-finger antiviral protein (ZAP) was a host factor 
to prevent retroviral Moloney murine leukemia virus (MLV) infection in 2002 
(Gao et al., 2002). The minimum required region is the rat N-terminal ZAP 
(rZAP) that contains only the zinc-finger domain (Figure 3.1). Subsequent 
studies showed that, in addition to retroviral MLV, overexpression of ZAP 
inhibits replication of many viruses in cells, including several members in the  
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Figure 3.1 The diagram showing domains in different ZAP isoforms. 
There are two dominant ZAP isoforms in human cells. The longer isoform 
ZAPL contains N-terminal zinc fingers domain, internal TPH and WWE 
domain, and C-terminal PARP-like domain. The shorter isoform ZAPS 
contains identical C-terminal and internal domains, but lacks the C-terminal 
PARP-like domain. Rat cell contains one major shorter isoform the N-ZAP 
which is mainly the zinc fingers domain (Kerns et al., 2008). 
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positive-sense ssRNA Alphavirus (Sindbis virus, Semliki Forest virus, Ross 
River birus and Venezuelan equine encephalitis virus) (Bick et al., 2003), and 
negative-sense ssRNA Filovirus (Ebola virus and Marburg virus) (Muller et al., 
2007). Recent studies showed ZAP also inhibits HIV-1 (positive-sense ssRNA ) 
and Hepatitis B virus (partial dsDNA) (Mao et al., 2013; Zhu et al., 2011). 
However, ZAP does not have universal antiviral activity since ZAP does not 
inhibit replication of vesicular stomatitis virus (negative-sense ssRNA), 
poliovirus (positive-sense ssRNA), yellow fever virus (positive-sense ssRNA) 
and herpes simplex virus type 1 (dsDNA) (Bick et al., 2003). It looks like ZAP 
has antiviral activity to retroviruses and some ssRNA viruses and only few 
DNA virus. In addition, the inhibition of viral replication can be up to 3 to 4 log 
units when cells are infected with high multiplicity of infection (MOI) and even 
more in low MOI, suggesting very robust inhibition of viral replication. 
3.1.2 ZAP binds specifically to the cytoplasmic viral mRNA and leads to 
its degradation 
    The N-terminal zinc-fingers of ZAP is the major antiviral functional domain. 
Before the discovery of human ZAP in 2008 (Kerns et al., 2008), most studies 
used rat N-terminal ZAP (rZAP) as a model to study its antiviral functions. 
ZAP was found to block Sindbis virus replication after the virus binding to cells, 
penetration and uncoating, but before the amplification of newly synthesized 
positive strand genomic RNA. In addition, the translation of incoming viral 
RNA was found to be blocked by ZAP (Bick et al., 2003). The MLV 
experiments showed that the cytoplasmic viral mRNA level is decreased in the 
presence of ZAP while the nuclear viral mRNA level is not affected (Gao et al., 
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2002). Later, ZAP was further shown to directly bind to and downregulate 
specific viral mRNAs through mainly the second and fourth zinc fingers (Guo 
et al., 2004; Muller et al., 2007). However, no specific consensus mRNA 
sequence could be mapped so far since different virus mRNAs have different 
ZAP binding regions (ZAP responsive element, or ZRE). Further sequence 
analysis of different ZAP binding mRNA fragments did not identify any 
common characteristics structures, so it remains unclear how ZAP recognizes 
specific viral mRNA (Guo et al., 2004). 
For the mechanism by which ZAP downregulates viral mRNA, study has 
demonstrated that ZAP can recruits the RNA processing exosome to degrade 
the target viral mRNA (Guo et al., 2007a). Because mRNA is highly structured, 
ZAP may need other factors for efficient mRNA degradation. Further study 
showed that certain RNA helicase (p72 DEAD box RNA helicase), as a ZAP-
interacting protein, is required to promote ZAP-mediated RNA degradation 
(Chen et al., 2008). In addition, in HIV-1 infected cells the 5’ decapping 
complex through association with RNA helicase p72, and 3’ poly(A)-speciﬁc 
ribonuclease (PARN) were recruited by ZAP to promote the viral mRNA 
degradation (Zhu et al., 2011). Based on these studies, the current working 
model for ZAP antiviral activity is that ZAP specifically binds to target viral 
mRNA containing ZAP-responsive element (ZRE) through mainly the second 
and fourth zinc-finger motifs, and recruits many cellular proteins involved in 
RNA degradation including p72 RNA helicase to resolve RNA structure for 
efficient degradation, and decapping complex (DCP) to degrade mRNA from 
5’end, and poly(A)-speciﬁc ribonuclease (PARN) to degrade 3’ poly A tail, and 
RNA exosome to degrade RNA body from 3’end (Figure 3.2). 
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Figure 3.2 Diagram showing the mechanism of ZAP-mediated viral 
mRNA degradation. ZAP via its zinc fingers targets ZAP-responsive element 
(ZRE)-containing viral mRNA, and then recruits many cellular proteins 
including p72 RNA helicase to resolve RNA structure, and decapping complex 
(DCP) to degrade mRNA from 5’end, and poly(A)-speciﬁc ribonuclease (PARN) 
to degrade 3’ poly A tail, and RNA exosome to degrade RNA body from 3’end. 
 
 
 
 
 
 
 
 
 
 
58 
 
In addition to its antiviral activity, the cellular function of ZAP zinc-finger 
domain is unclear. Since ZAP can promote degradation of specific viral mRNA, 
it is reasonable that ZAP may also regulate or be involved in specific cellular 
mRNA processing or metabolism. Recently a study showed that human ZAPL, 
also known as PARP13, destabilizes cellular mRNAs including TRAILR4 post-
transcriptionally to regulate TRAIL-mediated apoptosis in the absence of viral 
infection (Todorova et al., 2014), indicating ZAP and its specific ZAP binding 
sequence may represent a novel mechanism to regulate cellular mRNA 
stability. 
3.1.3 The mechanism by which ZAPL PARP domain contributes to 
antiviral activity is unclear 
    The antiviral function of ZAP N-terminal zinc finger domain has been well-
established; however, much less is known about how ZAPL PARP domain is 
involved in antiviral functions. ZAP, also known as PARP13, belongs to the 
poly(ADP-ribose) polymerase (PARP) protein family. The primary function of 
PARP is to post-translationally modify its target protein with poly(ADP-ribose), 
or pADPr, which is also known as poly(ADP-ribosylation) or PARylation. 
However, it was reported that ZAPL PARP domain lacks the poly(ADP-
ribosylation) activity possessed by other cytoplasmic PARP proteins (Kleine et 
al., 2008). Interestingly, compared to ZAPS, ZAPL was shown to have 
stronger RNA degradation activity and stronger antiviral activity against 
Semliki Forest virus and Moloney murine virus. However, the underlying 
mechanism for how PARP domain enhances antiviral activity remains unclear 
(Kerns et al., 2008). Subsequent study showed that S-farnesylation of a Cys 
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in the PARP domain leads ZAPL to associate with endo/lysosomes, which 
contributes the enhanced ZAPL antiviral activity against Sinbis virus. However, 
the mechanism by which endo/lysosomes association contributes to stronger 
RNA degradation activity and antiviral activity of ZAPL remains to be further 
investigated (Charron et al., 2013). Another study showed although the ZAPL 
PARP domain lacks the poly(ADP-ribosylation) activity due to inactive catalytic 
triad motif, such inactive triad motif are required for its antiviral activity against 
Sindbis virus. Mutation of the inactive triad motif to triple alanines or catalytic 
active triad motif possessed by other functional active PARPs abolished 
ZAPL’s antiviral activity (Glasker et al., 2014). To conclude, the mechanism by 
which ZAPL PARP domain contributes to antiviral activity is still unclear. 
Further, whether such antiviral activity is dependent on zinc-finger antiviral 
activity or not is also unknown. 
3.1.4 ZAP serves as a PARP protein that regulates stress responses and 
microRNA activity in cells 
    ZAP serves as a PARP protein which is also involved in other cellular 
function. Poly(ADP-ribosylation) was best known for its functions in the 
nucleus to regulate transcription, chromosome structure, and DNA damage 
repair (Krishnakumar and Kraus, 2010). Accumulated studies showed 
Poly(ADP-ribosyaltion) is also involved in cytoplasmic functions. Recent study 
from Phillip Sharp and Paul Chang Lab showed that poly(ADP-ribosylation) is 
required for the assembly of cytoplasmic stress granules (SG), which 
regulates mRNA stability and translation upon stress. Several PARP proteins 
including ZAP (PARP13) were identified associated with SG. Although 
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PARP13 is lack of PARP activity, PARP13 probably cooperates with other 
PARP proteins (PARP12 and 15) to poly-ADP-ribosylate the microRNA-
binding Argonaute proteins upon stress, which inhibits microRNA-mediated 
translation repression and microRNA-directed mRNA cleavage (Leung et al., 
2011). 
    In the present study, we revealed the antiviral role of ZAPL C-terminal 
PARP domain against influenza A virus. We showed that the ZAPL PARP 
domain targets the viral polymerase PA and PB2 proteins. These two viral 
polymerases are poly(ADP-ribosylated), presumably by other PARP protein(s), 
which enhances the ZAPL-PA and ZAPL-PB2 interaction. The ZAPL-
associated, poly(ADP-ribosylated) PA and PB2 are then ubiquitinated and 
proteasomally degraded. Such ZAPL antiviral activity is counteracted by the 
binding of polymerase PB1 protein to an adjacent WWE region, which 
displaces PA and PB2 from ZAPL and thus escape degradation. Because PB1 
displaces PA and PB2 and protects them from ZAPL-mediated degradation, 
endogenous ZAPL only moderately inhibits influenza A virus replication (20-
30-fold), as determined by siRNA knockdown experiment. These results 
indicate that influenza A virus has partially won the battle against the newly 
identified ZAPL antiviral activity. 
3.2 Materials and Methods 
3.2.1 Cell-lines and recombinant viruses 
    HEK-293T human kidney cell-line (ATCC CRL-11268), HEL299 human 
lung fibroblast cells (ATCC CCL-137), Madin-Darby canine kidney cell-line 
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(MDCK) (ATCC CCL-34), and Calu3 human lung adenocarcinoma cell-line 
(ATCC HTB-55) were purchased from ATCC. 293T, HEL299 and MDCK cells 
were grown in Dulbecco's modified Eagle's medium (DMEM) (GIBCO) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GIBCO), 2 
mM l-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin (1% PSG) 
(GIBCO) at 37°C under a 5% CO2/95% air atmosphere. Calu3 cells were 
grown in Advanced MEM (GIBCO) supplemented with 10% FBS and 1% PSG 
at 37°C under a 5% CO2/95% air atmosphere. 
Influenza A wild-type Ud virus, and Ud virus encoding NS1 and NS2 
proteins with a N-terminal 1xFlag tag were generated by plasmid-based 
reverse genetics as described in details in Section 2.2.1. All eight genomic 
RNA segments of recombinant viruses were sequenced. Virus stocks were 
grown in 10-day-old fertilized eggs, and virus titers were determined by 
plaque assays in MDCK cells. 
3.2.2 Plasmids and antibodies 
    Human ZAPL and ZAPS cDNAs were cloned by RT-PCR of RNA isolated 
from human HEL299 cells. The primers used to generate these two cDNAs 
are shown in Table 3.1. The ZAPL C88R mutation was introduced into ZAPL 
using standard oligonucleotide mutagenesis methods. Each cDNA was cloned 
into the pcDNA3 mammalian expression vector. All constructs were confirmed 
by sequencing. The LlucSN plasmid was provided by Harmit Malik to assay 
the mRNA degradation activity of ZAP (Kerns et al., 2008). Rabbit antibody 
against PB1 was provided by Krister Melen and Ikka Julkunen. Monoclonal 
antibodies against PA and PB2 were provided by Juan Ortin  
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Table 3.1 Primer sequences used in this study 
Target    Purpose     Strand               Sequence 
ZAPL                Forward      5’- ATG GCG GAC CCG GAG GTG 
ZAPL                Reverse      5’- CTA ACT AAT CAC GCA GGC 
ZAPS                Forward      5’- ATG GCG GAC CCG GAG GTG 
ZAPS                Reverse      5’- CTA TCT CTT CAT CTG CTG 
PA       RT-PCR     Forward      5’- GAA ATG GGG AAT GGA GAT GA 
PA       RT-PCR     Reverse      5’- CAT GCT CTC GAT TTG TTG GA 
 
Table 3.2 siRNA sequences used in this study 
Target                  Sequence (complimentary sequence not shown) 
ZAPL                   5’- AAA UUU AUC CAG GAG CUC UGA GUU C 
PARG                   5’- GAA AUA UUU CUA GCC UGA AUG UAG A 
Control                  5’- UUG AUG UUG AGC AAU UCA CGU UCA U 
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(Ochoa et al., 1995). Antibody against the major structural proteins of Ud virus, 
which detects NP as well as HA and M1 (denoted as Ub Ab), was provided by 
Robert A. Lamb (Chen et al., 2007). The antibody against amino acids 300 - 
400 of human ZAPS and ZAPL was from Abcam. Tubulin antibody was from 
Cell Signaling, and polyclonal antibody against poly(ADP-ribosylation) was 
from BD-Pharmingen (LP96-10) (Leung et al., 2011). 
3.2.3 siRNA knockdown of ZAPL and PARG 
    Knockdown of ZAPL by siRNA was performed to determine whether 
ZAPL has functional impact on influenza Ud virus replication in A549 cells. 
The siRNA duplexes specifically against ZAPL (but not ZAPS) was designed 
and purchased through Invitrogen (Stealth RNAi™ siRNAs) using sequence 
of ZAPL C-terminal PARP domain. The sequence of ZAPL siRNA is shown in 
Table 3.2. To determine the role of poly(ADP-ribosylation) in ZAPL’s antiviral 
function, siRNA knockdown of PARG which is an enzyme to hydrolyze 
poly(ADP-ribose) chain was performed in 293T cells, and the siRNA 
sequence is shown in Table 3.2. The control siRNA is a scrambled siRNA 
sequence with no known human gene target. The knockdown experiment was 
performed using either siRNA against target gene or control siRNA mixed with 
X-tremeGENE siRNA Transfection Reagent (Roche) according to the 
manufacturer’s protocol.  
In brief, for maximal knockdown efficiency in A549 cells, cells were 
trypsinized, washed and re-suspended in serum- and antibiotics-free Opti-
MEM I. At 6 - 8 hours after addition of siRNA mixture into re-suspended A549 
cell cultures, medium was replaced with fresh DMEM with 10% FBS and 1% 
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PSG. Final concentration of 40 nM siRNA was used for ZAPL knockdown in 
A549 cells for 36 - 48 hours before virus infection. For siRNA knockdown in 
293T cells, no trypsinization and resuspension of cells are needed. The siRNA 
and transfection reagent mixture was added into cell culture that have been 
replaced with fresh DMEM containing 10% FBS and 1% PSG. Final 
concentration of 50 - 80nM siRNA was used for PARG knockdown in 293T 
cells for 36 - 48 hours. 
3.2.4 RNA Extraction, Semi-quantitative Reverse Transcription (RT)-PCR, 
and Quantitative RT-PCR 
    Total RNA in cells is harvested by using Trizol reagent (Invitrogen) and 
chloroform according to manufacturer’s instructions. cDNA is generated from 
reverse transcription of total mRNA with oligo-dT primer, which is then PCR 
amplified with specific primers to each candidate target genes (shown in Table 
3.1). Amplified PCR products are separated by electrophoresis on 1% 
agarose. To quantitate PA mRNA levels in the transfection assay to determine 
whether ZAP leads to PA mRNA degradation, RNA was extracted from cell, 
polyadenylated mRNA was isolated using oligo(dT)-coated beads (Qiagen), 
and reverse transcribed using an oligo-dT primer. PCR amplification of PA 
mRNA and β-actin mRNA was carried out using Ud PA specific primers 
(shown in Table 3.1), and β-actin specific primers, respectively, and the 
FastStart Universal Probe Master Mix (Rox) with Universal Probe Library 
#134 for Ud PA or #64 for human β-actin. Analysis was carried out using the 
Perkin-Elmer/Applied Biosystems 7900HT sequence detector. The C-T value 
for PA mRNA was normalized to the C-T value of β-actin mRNA. The 
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quantitative RT-PCR reactions were performed in triplicate. 
3.2.5 Luciferase assay of mRNA-degrading activity of ZAP 
To determine the different ZAP constructs are functional active in 
targeting viral mRNA for degradation, a reporter luciferase assay established 
by others was performed (Kerns et al., 2008). 293T cells were transfected 
using the Mirius TransIT-LTR Transfection reagent with 50 ng of the LlucSN 
plasmid, 25 ng of the pcDNA3 plasmid expressing renilla luciferase, and 
either an empty pcDNA3 vector (No ZAP control) or one of the following 
plasmids: ZAPL (0.5 μg), ZAPS (0.2 μg), or ZAPL-C88R (1.2 μg). These 
levels of the different ZAP plasmids resulted in equal expression of the 
encoded proteins, as shown by an immunoblot probed with the ZAP antibody. 
The total amount of transfected plasmids was equalized by the addition of the 
empty pcDNA3 plasmid. After 24 hours of transfection, cells from triplicate 
transfections were collected, and the activities of the two luciferases activity in 
cell extracts were determined using a Mithras microplate luminometer. 
3.2.6 Virus infection and plaque formation assay 
    To determine the multiple cycle growth of Ud virus in ZAPL knockdown 
cells, A549 cells with ZAPL knockdown for 36 - 48 hours were infected with 
Ud virus at 0.05 pfu/cell (low M.O.I.). A549 cells were washed and incubated 
with diluted Ud virus in serum-free DMEM containing 1% BSA and 1% PSG. 
After 1 hour incubation, cells were washed with PBS and replaced with DMEM 
containing 1 µg/ml N-acetylated trypsin and 1% PSG. At indicated time post 
infection, small amount of supernatant from cell culture was harvested and the 
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virus titer was determined by plaque formation assay as described in section 
2.2.7. 
3.2.7 Co-immunoprecipitation experiment 
    To study protein-protein interaction, co-immunoprecipitation experiment 
was performed. Cells were co-transfected using the Mirius TransIT-LTR 
transfection reagent with the two or three plasmids indicated in the text, and 
were extracted with lysis buffer containing 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 5 mM EDTA, 2.5 mM MgCl2, 1% NP40, 10% glycerol, 1 mM PMSF, and 
1x Protease inhibitor (Roche). Cell extracts were diluted with lysis buffer 
containing 50 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM PMSF, and 1x 
Protease inhibitor to make final concentration of 0.5% NP40 and then 
immunoprecipitated with the antibody against one of the expressed proteins 
or tubulin antibody as a negative control, followed by binding to mixture of 
Protein A/G Sepharose beads (GE Health). After washing the Sepharose 
beads four times with wash buffer containing 50 mM Tris-HCl pH7.5, 150 mM 
NaCl, 0.5% NP40, proteins were eluted by heating the beads at 95℃ in a 
sample buffer containing 50 mM Tris-HCl pH6.8, 2% SDS, 6% glycerol, 2% β-
mercaptoethanol. The eluate was resolved by electrophoresis on a SDS-
PAGE gel, which was then analyzed by immunoblots probed with the antibody 
against the protein(s) expressed by each plasmid(s) or with tubulin Ab as 
internal loading control. 
3.2.8 Ubiquitination assay 
    To study whether certain protein is ubiquitinated and proteasomally 
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degraded, ubiquitination assay was performed. 293T cells were co-
transfected with the plasmids indicated in the text, and, where indicated, were 
then treated with 40uM MG132 (Biomol International) which is a proteasome 
inhibitor to block proteasome function. Cells were extracted with lysis buffer 
supplemented with three deubiquitinase inhibitors: 5mM NEM (Sigma), 20uM 
PR-169, 5mM 1,10-phenanthroline (LifeSensors). Cell extracts, after reducing 
the NP40 concentration to 0.5%, were incubated with agarose beads 
conjugated with tandem ubiquitin-binding domains (TUBE-2, LifeSensors) to 
select for ubiquitinated proteins. After washing the TUBE-2 beads four times 
with wash buffer containing 50 mM Tris-HCl pH7.5, 300 mM NaCl, 0.5% NP40, 
proteins were eluted by heating the beads for 5 minutes at 95℃ in sample 
buffer containing 50mM Tris-HCl pH6.8, 2% SDS, 6% glycerol, 2% β-
mercaptoethanol. The eluate was subjected to electrophoresis on a SDS-
PAGE gel, followed by immunoblots probed with the indicated antibodies. 
3.2.9 Poly-(ADP-ribosylation) assay 
    To study whether certain protein is poly-ADP-ribosylated, a poly-(ADP-
ribosylation) assay with modified pADPr lysis buffer and procedure from 
previous study was performed (Leung et al., 2011; Seo et al., 2013). At least 
2x107 of 293T cells were co-transfected with the plasmids indicated in the text, 
and, where indicated, were then treated with 40uM MG132 to block 
proteasome function. Cells were extracted with a modified pADPr lysis buffer 
containing 50 mM HEPES pH7.4, 150 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 
1% TX-100, 1 mM DTT, 10 uM nocodazole (Sigma), 10 ug/mL cytochalasin D 
(Enzo Life Science), 1 uM PARG inhibitor ADP-HPD (EMD millipore), 1mM 
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NAD+ (Sigma), 1 mM PMSF, and 1x Protease inhibitor (Roche). Cell extracts 
were incubated with Flag-antibody-conjugated agarose M2 beads (Sigma) to 
immunoprecipitate Flag-PA or Flag-PB2; or Flag-Z2 ZAP fragment. After 
washing the agarose beads three times with the pADPr buffer containing a 
higher concentration of NaCl (300mM), proteins were eluted by incubating the 
beads with 500ug/mL 3xFlag peptides (Sigma) for Flag-tagged protein elution. 
The Flag eluate or the V5-immunoprecipitates was heated at 70℃ for 8 
minutes in sample buffer containing 60mM Tris-HCl pH6.8, 2% SDS, 10% 
glycerol, 1.25% β-mercaptoethanol, and was then subjected to 
electrophoresis on a SDS-PAGE gel, which was then analyzed by 
immunoblots probed with an antibody against pADPr (LP96-10, BD-
Pharmingen) or the antibody against the indicated protein (Leung et al., 2011; 
Seo et al., 2013). 
3.2.10 Generation of pseudo-retrovirus 
    Instead of plasmid transfection into cells for protein expression, some 
experiments in present study employed pseudo-retrovirus infection to express 
specific viral protein in cells (i.e. PA and PB2 in this study). To make the 
retrovirus expressing indicated proteins in cells, the influenza Ud virus PA, 
PB2 or PB2 with C-terminal 1xFlag were cloned into a modified pQCXIP 
retroviral vector provided by Steven Goff Lab using either standard cloning or 
a modified SLIC procedure (done by Mark Collin) (Li and Elledge, 2007). 
For PA the primers were: 
Forward: 5’- ATGGAAGATTTTGTGCGACAATGCTTCAATTCGATG-3’; and 
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Reverse: 5’- CTATCTTAATGCATGTGTTAGGAAGGAGTTGAACCAAG-3’ 
For PB2 the primers were: 
Forward: 5’- ATGGAAAGAATAAAAGAACTACGGAATCTGATGTCGC-3’; and 
Reverse: 5’- TTAATTGATGGCCATCCGAATTCTTTTGGTCGCTG-3’ 
All constructs were confirmed by sequencing. To generate retrovirus, 
293T cells were co-transfected with indicated retroviral vector, pcDNA3-Gag-
pol and pcDNA3-VSV-G for 48 hours to generate pseudo-retrovirus. The 
supernatant containing the released pseudo-retrovirus were collected, filtered 
by 0.22μm PES membrane and applied to the target cells for 24 hours to 
express desired proteins (Naldini et al., 1996). 
3.2.11 Immunofluorescence by confocal microscopy 
    To determine the cellular localization where ZAPL interacts with PA, PB2 
and PB1, immunofluorescence by confocal microscopy was performed (done 
by Ligang Zhou). In brief, 293T cells were transfected with GFP-PB1, PA-GFP, 
V5-ZAPL plasmid, where indicated, for 36 hours. The cells were then fixed 
with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. V5-
ZAPL was visualized using mouse anti-V5 antibody and Alexa fluor 546 
conjugated goat anti-mouse antibody (Life technologies). Cell nuclei were 
stained with DAPI. Images were obtained using a Zeiss LSM 710 Confocal 
microscope, and data were processed with ZEN 2012 software. For PB2 
localization, Split-GFP strans-1-10 (Sandia Biotech) was cloned on to the C-
terminus of PB2, split-GFP strand-11 was cloned on to the N-terminus of 
ZAPL or ZAPS. 293T cells transfected with indicated plasmids were fixed, 
70 
 
permeabilized and stained with DAPI before they were used for direct 
fluorescence with the confocal microscope. All images were acquired using 
the same settings. 
3.3 Results 
3.3.1 ZAPL, which is associated with purified CPSF30-NS1 complexes, 
inhibits influenza A virus replication. 
    The CPSF30-NS1A protein complexes were purified from Ud virus 
infected cells as described in chapter 2 (Chen et al., 2014). 293T cells were 
transfected with GST-CPSF30 and then infected with wild-type Ud or Ud virus 
expressing Flag-NS1. The complexes were purified by GST pull down 
followed by Flag immunoprecipitation. Mass spectrometry analysis on the 
purified complexes has identified a list of associated host proteins. We have 
shown that the viral polymerase proteins PA, PB1, PB2, NP, and the cellular 
DDX21 RNA helicase are associated with the CPSF30-NS1A complexes. In 
addition, we surprisingly found substantial number of peptides of the cellular 
ZAP protein (13 peptide matches) in the 90 - 110 kDa region but not in the 
other molecular weight region from mass spectrometry results (Table 2.3). 
These results suggested that the CPSF30-NS1A complexes contain the 
longer ZAPL isoform (100 kDa), but not the shorter ZAPS isoform (78 kDa) 
lacking the C-terminal PARP domain (Figure 3.3A). To verify it is the ZAPL 
isoform that associates with the CPSF30-NS1A complexes, immunoblotting 
with ZAP antibody raised against N-terminal region (Abcam) shared by two 
isoforms was performed. Consistent with mass spectrometry results, only the 
ZAPL protein, but not the ZAPS protein, was detected in the purified CPSF30-  
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Figure 3.3 ZAPL, which is associated with purified CPSF30-NS1 
complexes, inhibits influenza A virus replication. (A) The domains in 
human ZAPL and ZAPS. (B) Immunoblot to confirm ZAPL association in 
purified CPSF30-NS1 complexes. (C) Immunoblot to measure the amounts of 
ZAPL and ZAPS in cells after Ud virus infection. (D) 293T cells were 
transfected with the ZAPL plasmid or a control plasmid for 40 hours, followed 
by infection with 0.1 pfu/cell of Ud virus. At the indicated times after infection, 
cell extracts were immunoblotted with ZAPL, Ud or tubulin Ab. (E) A549 cells 
were transfected with a ZAPL-specific or a control siRNA for 36 hours, 
followed by infection with 0.05 pfu/cell of Ud virus. Virus production at the 
indicated times after infection was determined by plaque assays. The bars 
show the standard deviation of triplicate of virus production. The efficiency of 
ZAPL knockdown is shown in the immunoblot of cell extracts probed with 
ZAPL Ab. 
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NS1A complexes (Figure 3.3B), but not in the control sample, indicating ZAPL 
is associated with the CPSF30-NS1A complexes. Endogenous ZAP 
expression level during Ud virus infection was determined in 293T cells. Both 
ZAPL and ZAPS are expressed in virus infected cells, and ZAPL expression 
predominates whereas ZAPS expression is reduced about 2-fold over virus 
infection. In addition, ZAPL protein level remains similar through virus 
infection (Figure 3.3C). 
    To establish whether endogenous ZAPL plays a role in virus replication, 
we first determine whether overexpression of ZAPL affects viral protein 
synthesis in 293T cells. No effect was seen when cells were transfected with 
low amount of ZAPL and infected with high M.O.I. of Ud virus (data not 
shown). However, overexpression of high amount of ZAPL reduced viral 
protein synthesis approximately 2-4 fold when infected with low M.O.I. of Ud 
virus (0.1 pfu/cell) (Figure 3.3D), suggesting ZAPL inhibits Ud virus replication. 
To verify whether endogenous ZAPL inhibits Ud virus replication, we 
transfected A549 human lung cells with ZAPL-specific siRNA to efficiently 
knock down endogenous ZAPL. Multiple cycle growth of Ud virus from low 
M.O.I. infection (0.05 pfu/cell) in A549 cells with ZAPL knockdown or control 
knockdown were performed, and viral productions were determined at 36 and 
60 hours after infection (Figure 3.3E). Interestingly, replication of Ud virus was 
enhanced by 20-30 fold in ZAPL knockdown cells compared to cells 
transfected with control siRNA, demonstrating that endogenous ZAPL 
moderately inhibits influenza A virus replication in human cells. 
3.3.2 ZAPL binds to PB1 protein and reduces protein levels of PA and 
73 
 
PB2. 
    As the first approach to study the mechanism by which ZAPL inhibits 
influenza virus replication, we determined which protein(s) that ZAPL interacts 
with in the CPSF30-NS1A complexes. Co-immunoprecipitation experiment 
was performed to study protein-protein interaction. 293T cells were 
transfected with plasmid expressing each component protein in the CPSF30-
NS1A complexes, i.e. PA, PB1, PB2, NP and NS1 individually, with or without 
co-transfection with ZAPL plasmid. Cell extracts were then 
immunoprecipitated with ZAPL, followed by immunoblots probed with Abs 
against each protein. Among the proteins tested, ZAPL only interacts with PB1 
and NP (Figure 3.4A-B), suggesting that ZAPL likely through binding to these 
two proteins associates with CPSF30-NS1A complexes. Further RNase 
treatment showed that ZAPL interacts with PB1 in a RNase-resistant manner, 
indicating involvement of protein-protein interaction (Figure 3.4A, lane 2). In 
contrast, RNase treatment disrupted ZAPL-NP interaction, indicating this 
interaction is RNA-mediated and likely nonspecific (Figure 3.4B, lane 2). For 
this reason, we only focused on ZAPL-PB1 protein-protein interaction in 
subsequent experiments. The interaction of ZAPL with PB1 is not limited to 
PB1 from Ud virus, ZAPL also interacts with PB1 from pandemic H1N1 
influenza A/CA/04/09 virus in a RNase-resistant manner, indicating the ZAPL-
PB1 interaction is not Ud-specific (Figure 3.4C). To confirm that ZAPL 
interacts with PB1 in infected cells, cells were transfected with ZAPL and then 
infected with Ud virus. The ZAPL immunoprecipitates verifies the ZAPL-PB1 
interaction in infected cells (Figure 3.4D). 
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Figure 3.4 ZAPL interacts with PB1 in a RNase-resistant manner and 
interacts with NP in a RNase-sensitive manner. (A) 293T cells were 
transfected with PB1 and with or without ZAPL plasmid. Cell extracts were 
immunoprecipitated with ZAPL Ab or tubulin Ab as a control, and were then 
treated with or without RNase A (5 μg/ml). The immunoprecipitates were then 
immunoblotted with ZAPL or PB1 Ab. (B) Cells were transfected with NP and 
with or without ZAPL plasmid. Cell extracts were immunoprecipitated with 
ZAPL Ab or tubulin Ab, and were then treated with or without RNase A. The 
immunoprecipitates were then immunoblotted with ZAPL or NP Ab. (C) Cells 
were transfected with ZAPL and a PB1 plasmid of H1N1 influenza A/CA/04/09 
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virus. Same immunoprecipitation and immunobloting were performed. (D) 
Cells transfected with or without ZAPL plasmid were then infected with Ud 
virus at 0.1 pfu/cell. Cell extracts collected at 9 hours post infection were 
immunoprecipitated with ZAPL. The immunoprecipitates were then 
immunoblotted with ZAPL or PB1 Ab. 
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Figure 3.5 Plasmid-expressed ZAPL leads to protein reduction of PA and 
PB2, but not PB1, NP and NS1. (A) 293T cells were transfected with NS1, 
PB1, NP, PB2 or PA and with or without ZAPL plasmid, respectively, and cell 
extracts were immunoblotted with Ab against ZAPL, tubulin and the indicated 
co-expressed proteins. (B-C) Cells were transfected with PB2 or PA of the 
indicated influenza A virus strain and with or without ZAPL plasmid. Cell 
extracts were immunoblotted with PB2, PA, ZAPL, or tubulin antibody. 
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We did not detected ZAPL interaction with the other tested proteins (PA, 
PB2 and NS1). Interestingly, when we checked the cell extracts prior to co-
immunoprecipitation experiments, we found PA and PB2 protein level were 
significantly and consistently reduced when co-transfected with ZAPL, 
suggesting ZAPL may play an inhibitory role against influenza virus. In 
contrast, co-transfection of ZAPL did not lead to reduction of PB1, NP or NS1 
protein level (Figure 3.5A). PA and PB2 from different influenza virus strains 
were also tested. Figure 3.5B showed that ZAPL overexpression led to 
reduction of PB2 from both H3N2 influenza A/Bris/10/07 and pandemic H1N1 
A/CA/04/09 strains. Figure 3.5C showed that ZAPL overexpression led to 
reduction of PA from both H5N1 influenza A/HK/483/97 and H1N1 A/TX/36/91 
strains. These results indicate the effect of ZAPL on PA and PB2 protein 
reduction is not Ud-specific, and ZAPL may play a general inhibitory role 
against multiple influenza A viruses. 
3.3.3 The C-terminal PARP domain, but not the RNA-binding activity of 
the N-terminal zinc-fingers of ZAPL is required for PA protein reduction 
    Previous studies have established the working model for ZAP’s antiviral 
activity against other viruses. ZAPL specifically binds to target viral mRNAs 
via N-terminal zinc-fingers domain and promotes degradation of these viral 
mRNAs, thus inhibits viral replication (Bick et al., 2003; Gao et al., 2002; Guo 
et al., 2004; Guo et al., 2007a; Kerns et al., 2008; Muller et al., 2007; Zhu et 
al., 2011). We first tested whether viral mRNA degradation is the underlying 
mechanism by which ZAPL leads to PA and PB2 protein reduction. To test this, 
ZAPL with second zinc-finger C88R mutation that has been shown to lose 
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Figure 3.6 The RNA-degradation activity of the ZAPL N-terminal zinc-
fingers is not involved in protein reduction of PA. (A-B) Luciferase 
reporter assay of mRNA degradation activity of ZAP proteins. 293T cells were 
transfected with 50ng of the LlucSN luciferase reporter plasmid and either 
ZAPL, ZAPS, ZAPL-C88R, or control plasmid. To determine transfection 
efficiency, 50ng of Renilla luciferase plasmid was included. After 24 hours of 
transfection, cells were collected, and the activities of the two luciferases in 
cell extracts were determined. The Firefly/Renilla ratio is shown as a percent 
of the control (C=No ZAP). Transfections were carried out in triplicate, and 
error bars are shown. The ZAP immunoblot shows that equal amounts of the 
three ZAP proteins were produced. (C) Effect of increasing amounts of ZAPL, 
ZAPS, or ZAPL-C88R plasmid on the protein expression of PA plasmid. (D) 
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Semi-quantitative RT-PCR of PA mRNA in cells transfected with the PA with 
either ZAPL, ZAPS, ZAPL-C88R, or control plasmid. Polyadenylated mRNA 
was isolated using oligo-dT-conjugated beads (Qiagen), and the amount of PA 
mRNA was determined by RT-PCR using specific primers. (E) Quantitative 
RT-PCR of PA mRNA in cells transfected with the PA and with or without ZAPL 
plasmid. Reactions were carried out in triplicate. The PA mRNA level in the 
presence of ZAPL was normalized to that without ZAPL. Error bars are shown. 
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RNA-binding and RNA degradation activities was constructed (Guo et al., 
2004) and tested whether such mutant ZAPL can reduce PA and PB2 protein 
level. We first verified that the ZAPL-C88R zinc-finger mutant indeed lose 
ability to degrade its target viral mRNA by using an luciferase reporter assay 
for ZAP-mediated RNA degradation established in study by Kerns et al., 2008. 
The LlucSN reporter used in this assay contains a MLV sequence which can 
be targeted by ZAP, and once targeted and degraded, the luciferase activity 
decreases. Figure 3.6A showed that ZAPL with C88R mutation indeed lose 
ability to target mRNA. Consistent with results from study by Kerns et al., 
2008, ZAPL shows strong activity against viral mRNA, whereas ZAPS also 
causes RNA degradation with less efficiency than ZAPL. Figure 3.6B showed 
the transfection efficiency was similar between these different plasmids by 
measuring the activity of Renilla luciferase which does not contain target 
sequence of ZAP. We next tested these different ZAP proteins on their ability 
to affect PA protein level. Cells were transfected with PA and increasing 
amounts of either ZAPL, ZAPL-C88R mutant or ZAPS plasmid (Figure 3.6C). 
Surprisingly, the wild-type ZAPL and ZAPL-C88R mutant effectively reduced 
the amount of PA protein to essentially the same extent, showing that the RNA 
degradation activity of N-terminal zinc-finger domain of ZAPL is not involved in 
reducing PA protein level. Furthermore, ZAPS, which causes RNA 
degradation but lacks the C-terminal PARP domain, did not reduce PA protein 
level, demonstrating that the PARP domain has an important role in the 
reduction of PA, which is confirmed below. To further verify that RNA 
degradation was not involved in ZAPL-mediated inhibition of PA protein 
production, we determined the level of PA mRNA from cells transfected with 
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PA and and with or without different ZAP plasmids. The mRNAs with poly-A 
tail were purified with oligo-dT-beads (Qiagen) and RT-PCR with specific 
primers was performed. Semi-quantitative RT-PCR showed that level of PA 
mRNA was not affected by all tested ZAP proteins (Figure 3.6D), consistent 
with the conclusion from immunoblots in Figure 3.6C. Further quantitative RT-
PCR showed that ZAPL did not decrease the level of PA mRNA (Figure 3.6E). 
We conclude that ZAPL-mediated PA protein reduction is not due to the 
mRNA degradation mechanism by ZAPL zinc-finger. 
3.3.4 PB2 and PA bind to the ZAPL PARP domain and undergo 
proteasomal degradation, whereas PB1 binds to an adjacent region of 
ZAPL that contains the WWE domain and is not degraded. 
    The above results indicate that it is unlikely that the RNA-binding activity 
of the N-terminal zinc fingers of ZAPL is involved in its antiviral activity against 
influenza A virus. Accordingly, we next tested an alternative mechanism, 
whether plasmid-expressed ZAPL promotes proteasomal degradation of PA 
and PB2 proteins. To test this, cells were transfected with PA or PB2 and with 
or without ZAPL plasmid for 18 hours and then treated with the proteasome 
inhibitor MG132 or DMSO as control for 24 hours (Figure 3.7A-B). In cells co-
transfected with ZAPL, very low amount of PA or PB2 protein was detected in 
the absence of MG132 (lane 3 and 7). However, the protein levels of these 
two proteins were significantly increased by when proteasome function was 
blocked by MG132 (lane 4 and 8), suggesting the plasmid-expressed ZAPL 
leads to proteasomal degradation of PA and PB2. Interestingly, co-
immunprecipitation of these cells extracts with ZAPL showed that the PA and 
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Figure 3.7 PA and PB2 protein reduction by ZAPL can be rescued by 
MG132 treatment, in which ZAPL interacts with MG132-stabilized PA and 
PB2. (A-C) 293T cells were treated with 40μM MG132 or as 0.1% DMSO as a 
control after transfection with PB2 (A), PA (B) or PB1 (C) and with or without 
ZAPL plasmid as described in the text. For the PB2 and PA transfections 
(lanes 1-8), the extracts from DMSO-treated cells were immunoprecipitated 
with ZAPL Ab, followed by immunoblots with ZAPL and PA or PB2 Ab. The 
extract from MG132-treated cells was immunoprecipitated with ZAPL Ab or 
tubulin Ab as immunoprecipitation control, with or without subsequent RNase 
treatment. The imunoprecipitates were immunoblotted with ZAPL and PA or 
PB2 Ab. For the PB1 transfection (lanes 9-12), the cell extracts were 
immunoblotted with PB1, ZAPL and tubulin Ab. 
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PB2 protein that were rescued from proteasomal degradation by MG132 
treatment were bound to ZAPL in a RNase-resistant manner, suggesting that 
ZAPL binds to PA and PB2 to promote their degradation. Plasmid-expressed 
ZAPL was largely responsible for reducing PA and PB2 proteins, because PA 
and PB2 levels were lower than that in the absence of ZAPL plasmid, both 
with or without MG132 treatment (compare lane 1 and 2 to lane 3 and 4; lane 
5 and 6 to lane 7 and 8), suggesting MG132 treatment only partially rescued 
PA ad PB2 protein from plasmid-expressed ZAPL. Furthermore, in the 
absence of plasmid-expressed ZAPL, the PA and PB2 protein also rescued by 
MG132 treatment (lane 1 and 2; lane 6 and 7), and the MG132-stablized PA 
and PB2 proteins were bound to endogenous ZAPL in a RNase-resistant 
manner, suggesting endogenous ZAPL targets PA and PB2 to promote their 
proteasomal degradation in the absence of plasmid-expressed ZAPL, which 
was verified in the subsequent further experiments. On the other hand, the 
level of PB1 protein was not increased by MG132 treatment in the absence of 
plasmid-expressed ZAPL, and was only slightly increased less than 2-fold by 
MG132 treatment in the presence of plasmid-expressed ZAPL (Figure 3.7C), 
indicating that ZAPL specifically targets PA and PB2, but not PB1, for 
degradation. 
    Based on the result that the C-terminal PARP domain of ZAPL is required 
for PA protein degradation, we next determined whether ZAPL PARP domain 
is also required for binding to PA and PB2. We constructed two different ZAP 
fragments, Z1 that contains PARP domain and Z2 that contains WWE and 
PARP domain, and tested their ability to bind PA, PB2 and PB1 protein 
(Figure 3.8A). Cells were transfected with PB2 (Figure 3.8B), PA (Figure 3.8C) 
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or PB1 (Figure 3.8D) and V5-tagged wild-type ZAPL or ZAP fragments, and 
then treated with MG132 for PB2 and PA expressed cells to minimize PB2 
and PA degradation caused by endogenous or plasmid-expressed ZAPL. Cell 
extracts were immunoprecipiated with V5 antibody and immunoblotted with 
indicated Abs. The results showed that Z1 ZAP fragment comprising the 
PARP domain was sufficient for binding PB2 and PA, but not PB1, 
demonstrating that the PARP domain is responsible for binding PB2 and PA, 
but not PB1. The Z2 ZAP fragment comprising both WWE and PARP domains 
bound to PB1 almost as efficiently as the full-length ZAPL, indicating that PB1 
presumably binds to the ZAPL region containing WWE domain. Because the 
ZAP fragment containing WWE domain alone (580-700 aa) did not express 
well in cells, thus it was not available for further verification of PB1 binding in 
this approach. We conclude that the PARP domain is responsible for binding 
PB2 and PA, and is required for their degradation, whereas PB1 binds 
primarily to the adjacent ZAPL region containing WWE domain and is not 
degraded. 
Furthermore, we found that Z2 fragment bound significantly more PB2 
and PA than full-length ZAPL and Z1 fragment, and some of the Z2-bound 
PB2 and PA proteins were larger in size (lane 3 in Figure 3.8B, C), suggesting 
they were post-translationally modified. Compared to Z1, Z2 fragment 
contains one more domain, WWE domain, which has been shown to interact 
with poly-ADP-ribosylated chains (Wang et al., 2012), it is therefore likely that 
the PB2 and PA proteins associated with the Z2 fragment are poly-ADP-
ribosylated, which was verified in subsequent experiment. We hypothesized 
that the PB2 and PA proteins bound to the Z2 fragment are poly-ADP- 
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Figure 3.8 PB2 and PA bind to the ZAPL PARP domain, whereas PB1 
binds to an adjacent region of ZAPL that contains the WWE domain. (A) 
Diagram of the Z1 and Z2 fragments of ZAPL. Z1 (700–902 aa) contains 
PARP domain whereas Z2 (580–902aa) contains PARP and WWE domain. 
(B-D) 293T cells were transfected with PB2 (B), PA (C) or PB1 (D) with V5-
ZAPL, V5-Z2, or V5-Z1 or control plasmid. The PB2 and PA transfections 
were followed by MG132 treatment. Aliquots of the cell extracts were 
immunoblotted with the indicated Abs as input for immunoprecipitation. After 
immunoprecipitation with V5 Ab, the immunoprecipitates were immunoblotted 
with the indicated Abs. 
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ribosylated intermediates that require the full-length ZAPL protein for 
subsequent processing, i.e. ubiquitination that then leads to proteasomal 
degradation (see detail in Discussion). 
    ZAPL, also known as PARP13, has been shown to participate in cellular 
functions in cytoplasm (Leung et al., 2011), where ZAPL binds to endosomal 
membranes and/or is associated with stress granules (Charron et al., 2013; 
Leung et al., 2011). As a result, ZAPL would be expected to target PA, PB2 
and PB1 proteins in the cytoplasm. To verify that is the case, 
immunofluorescence by confocal microscopy was performed on cells 
transfected with PA, PB2 or PB1 and low amount of ZAPL to minimize 
degradation of PA and PB2 (Figure 3.9). Individually expressed PA and PB1 
proteins are localized primarily in the cytoplasm, whereas PB2 is mainly in the 
nucleus (Fodor and Smith, 2004). Figure 3.9A showed that ZAPL indeed 
interacts with PA or PB1 in the cytoplasm. To investigate that ZAPL also 
targets PB2 in the cytoplasm, split-GFP approach was used. Split-GFP strans-
1-10 (Sandia Biotech) was cloned on to the C-terminus of PB2, split-GFP 
strand-11 was cloned on to the N-terminus of ZAPL or ZAPS (as a negative 
control). In Figure 3.9B, GFP signal only can be seen in the cytoplasm when 
cells were co-transfected with PB2 and ZAPL, but not ZAPS, indicating ZAPL 
interacts with PB2 in the cytoplasm and confirming that PARP domain is 
required for binding PB2. 
3.3.5 Plasmid-expressed and endogenous ZAPL binds to PA and PB2, 
leading to their ubiquitination and proteasomal degradation. 
    Because proteins are ubiquitinated before they get proteasomal 
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degraded, we tested whether PA and PB2 are ubiquitinated prior to 
proteasomal degradation, and whether the ubiquitination requires ZAPL. Cells 
were transfected with PB2 or PA and with or without ZAPL plasmid. Where 
indicated, the transfected cells were then treated with MG132 or DMSO as 
shown in Figure 3.10. Ubiquitinated protein species in cell extracts were 
affinity selected by beads conjugated with tandem ubiquitin-binding domains 
(TUBE-2, LifeSensors), followed by immunoblot probed with PA or PB2 Ab. 
Multiple ubiquitinated protein species larger in size than PA or PB2 were 
detected in the cells transfected with ZAPL (Lane 2 in Figure 3.10A and B). 
Most of these ubiquitinated protein species were absent when PA and PB2 
were not protected against proteasomal degradation by MG132 treatment 
(Lane 3 in Figure 3.10A and B), indicating that the observed ubiquitinated 
proteins are PA and PB2 ubiquitin conjugates. 
    Interestingly, ubiquitinated PA and PB2 proteins were also detected from 
the cells without plasmid-expressed ZAPL and treated with MG132 (Lane 1 in 
Figure 3.10A and B). To determine whether endogenous ZAPL is responsible 
for the ubiquitination and degradation of PA and PB2, two different 
approaches were carried out. In the first approach, endogenous ZAPL was 
knocked down by specific siRNA. Cells were transfected with either control 
siRNA or siRNA specifically targets the ZAPL PARP domain so that only ZAPL 
but not ZAPS is knocked down. To avoid second exposure of the cells to 
transfection reagent, PB2 and PA were expressed from pseudo-retrovirus. 
Compared to control samples, siRNA knockdown of endogenous ZAPL 
effectively rescued PB2 and PA from degradation (Figure 3.11A). As a 
negative control, GFP expression from the same pseudo-retrovirus was not  
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Figure 3.9 ZAPL interacts with PB1, PA or PB2 in the cytoplasm. (A) 293T 
cells were transfected with GFP-PB1, PA-GFP, V5-ZAPL plasmid, where 
indicated, for 36 hours. The cells were then fixed with 4% paraformaldehyde 
and permeabilized with 0.5% Triton X-100. V5-ZAPL was visualized using 
mouse anti-V5 antibody and Alexa fluor 546 conjugated goat anti-mouse 
antibody (Life technologies). Cell nuclei were stained with DAPI. Images were 
obtained using a Zeiss LSM 710 Confocal microscope, and data were 
processed with ZEN 2012 software. (B) Split-GFP strans-1-10 (Sandia 
Biotech) was cloned on to the C-terminus of PB2, split-GFP strand-11 was 
cloned on to the N-terminus of ZAPL or ZAPS (as a negative control). 293T 
cells transfected with indicated plasmids were fixed, permeabilized and 
stained with DAPI before they were used for direct fluorescence with the 
confocal microscope. All images were acquired using the same experimental 
settings. (Done by Ligang Zhou) 
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Figure 3.10 PA and PB2 protein are ubiquitinated under MG132 treatment. 
(A-B) 293T cells were transfected with PB2 (A) or PA (B) and with or without 
ZAPL plasmid. Where indicated, the transfected cells were treated with 
MG132 or DMSO. Aliquots of the cell extracts were immunoblotted with the 
indicated Abs as input for immunoprecipitation. After binding the cell extracts 
to beads conjugated to tandem ubiquitin-binding domains (TUBE-2, 
LifeSensors), the bound proteins were eluted and immunblotted with PB2 or 
PA Ab. 
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affected by ZAPL knockdown. As the second approach, the Z2 ZAP fragment 
was overexpressed to interact and occupy PB2 and PA so that endogenous 
ZAPL cannot target them. Cells were transfected with increasing amounts of 
Z2 fragment and treated with retrovirus expressing PA or PB2. As shown in 
Figure 3.11B, overexpression of Z2 fragment rescued PB2 and PA protein 
from endogenous ZAPL-mediated degradation in a dose-dependent manner. 
As a negative control, Z2 overexpression did not affect the protein level of 
GFP expressed from pseudo-retrovirus. 
These results provide further evidences that ZAPL PARP domain binds to 
PB2 and PA to promote their degradation. The siRNA knockdown of ZAPL and 
Z2 overexpression results indicate that endogenous ZAPL is responsible for 
the degradation of PB2 and PA in the absence of plasmid-expressed ZAPL. 
We next determined whether endogenous ZAPL is also responsible for PB2 
and PA ubiquitination prior to proteasomal degradation. Cells were transfected 
with or without Z2 fragment, followed by infection with retrovirus expressing 
PB2 and then MG132 treatment. Total ubiquitinated proteins in cell extracts 
were selected with TUBE-2 beads. The overexpression of Z2 fragment 
significantly reduced the ubiquitination of PB2 that occurs in the absence of 
plasmid-expressed ZAPL without affecting the total protein ubiquitination in 
cells (Figure 3.12A). These results establish that endogenous ZAPL and 
plasmid-expressed ZAPL promote the ubiquitination and proteasomal 
degradation of PB2 and PA. 
We then determined whether ubiquitinated PB2 and PA proteins are bound to 
ZAPL. Cells were transfected with PB2 and with or without ZAPL plasmid, and  
92 
 
 
 
Figure 3.11 Endogenous ZAPL is responsible for PB2 degradation. (A) 
293T cells were transfected with control siRNA or ZAPL-specific siRNA for 36 
hours, and were then infected with retrovirus expressing either PB2, PA or 
GFP as control for 24 hours. Cell extracts were immunoblotted with the 
indicated Abs. (B) 293T cells were transfected with the indicated amounts of 
the V5-Z2 ZAP fragment plasmid for 48 hours, followed by infection with a 
retrovirus expressing PB2, PA or GFP for 24 hours. The cell extracts were 
immunoblotted with the indicated Abs. 
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Figure 3.12 ZAPL binds to PB2 and leads to its ubiquitination. (A) 293T 
cells were transfected with or without V5-Z2 plasmid for 40 hours, followed by 
infection with a retrovirus expressing PB2 and then MG132 treatment. An 
aliquot of the cell extracts was immunoblotted with the indicated Ab as input 
for immunoprecipitation. The cell extracts were selected on beads conjugated 
to tandem ubiquitin-binding domains (TUBE-2), and the eluate was 
immunoblotted with either PB2 or Ub Ab. (B) 293T cells were transfected with 
PB2 and with or without ZAPL plasmid, and then treated with MG132. Aliquots 
of the cell extracts were immunoblotted with the indicated Abs as input for 
immunoprecipitation. Cell extracts were immunoprecipitated with ZAPL Ab, 
and the immunoprecipitate was immunblotted with PB2 or Ub Ab. 
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then treated with MG132. Cell extracts were immunoprecipitated with ZAPL, 
and immunblotted with presence of PB2 and ubiquitination (Figure 3.12B). 
The result showed that PB2 and ubiquitinated protein species larger in size 
than PB2 were detected in ZAPL immunoprecipitates, indicating that 
ubiquitinated PB2 is bound to ZAPL. Taken together, these results indicate 
that PB2 and PA are ubiquitinated while they are bound to ZAPL. 
3.3.6 PB2 and PA are poly(ADP-ribosylated), but not by ZAPL, which is 
involved in ZAPL-mediated degradation. 
    Now we established that ZAPL PARP domain targets PA and PB2, 
leading to their ubiquitination and proteasomal degradation. We were 
wondering how PARP domain is involved in protein degradation pathway. 
Recent studies have provided some clues. The primary function of PARP 
protein is to post-translationally modify its target protein with poly-(ADP-ribose) 
chain, a process known as poly(ADP-ribosylation) or PARylation. Poly(ADP-
ribosylation) was best known for its functions in the nucleus to regulate 
transcription, chromosome structure, and DNA damage repair (Krishnakumar 
and Kraus, 2010). Accumulated studies showed poly(ADP-ribosylation) is also 
involved in cytoplasmic functions. One of which is that cytoplasmic PARP-
containing proteins can initiate proteasomal degradation by poly(ADP-
ribosylating) their target proteins, followed by ubiquitination catalyzed by an 
E3 ubiquitin ligase that recognize poly-ADP-ribose and the PARP protein to 
which the poly-ADP-ribosylated target protein is bound (DaRosa et al., 2014; 
Leung et al., 2011; Wang et al., 2012; Zhang et al., 2011a). However, the 
PARP domain of ZAPL (also known as PARP13.1) lacks the catalytic activity 
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for poly(ADP-ribosylation) (Kleine et al., 2008). It is likely that ZAPL 
cooperates with other PARP proteins to perform this activity, as previously 
shown by others (Leung et al., 2011). 
To study the underlying mechanism by which ZAPL PARP domain targets 
PA and PB2 for proteasomal degradation, we first determine whether PA and 
PB2 are poly(ADP-ribosylated). Cells were transfected with Flag-PB2 or Flag-
PA and with or without ZAPL plasmid, and then treated with MG132 or DMSO. 
Cell extracts were immunoprecipitated with Flag-antibody-conjugated beads, 
and then the immunoprecitates were eluted and immunoblotted with Ab 
against poly(ADP-ribose) chains (Figure 3.13) (Leung et al., 2011; Seo et al., 
2013). Multiple poly(ADp-ribosylated) protein species larger in size than PB2 
and PA were detected in cells expressed with ZAPL when proteasome 
degradation of PB2 and PA was inhibited with MG132 (Lane 2 and 4 in Figure 
3.13). These poly(ADP-ribosylated) protein species appeared as a smear 
larger in size of PB2 and PA because of the heterogeneity in the length of the 
poly(ADP-ribose) chain that were added, as previously shown by others 
(Leung et al., 2011; Seo et al., 2013). Most of these poly(ADP-ribosylated) 
protein species were absent when PB2 and PA were degraded in the absence 
of MG132 treatment (Lane 3 and 6 in Figure 3.13), indicating the observed 
poly(ADP-ribosylated) protein species are primarily poly(ADP-ribosylated) 
PB2 and PA proteins. 
Poly(ADP-ribosylated) PB2 and PA proteins were also detected from the 
M132-treated cells without plasmid-expressed ZAPL (Lane 1 and 4 in Figure 
3.13). To determine whether endogenous ZAPL is responsible for the  
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Figure 3.13 PA and PB2 protein are ploy-ADP-ribosylated under MG132 
treatment. (A-B) 293T cells were transfected with Flag-PB2 or Flag-PA and 
with or without ZAPL plasmid 40 hours. Where indicated, the cells were 
treated with MG132 or DMSO. An aliquot of the cell extracts was 
immunoblotted with the indicated Abs as input for immunoprecipitation. Cell 
extracts were immunoprecipitated with Flag-antibody-conjugated beads 
(Sigma) and the immunoprecipitates were analyzed by immunoblots probed 
with an Ab against pADPr (LP96-10, BD-Pharmingen). 
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poly(ADP-ribosylation) of PA and PB2, the ZAP fragment was overexpressed 
in cells to sequester PB2 and PA from endogenous ZAPL. Cells were 
transfected with V5-Z1 ZAP fragment or control plasmid, followed by infection 
with a retrovirus expressing PB2 with 1xFlag tag and then MG132 treatment. 
Cell extracts were immunoprecipitated with Flag-PB2 and Flag-PA to detect 
presence of poly(ADP-ribosylation) (Figure 3.14A). Interestingly, 
overexpression of Z1 ZAP fragment did not reduce the poly(ADP-ribosylation) 
of PB2 in the absence of plasmid-expressed ZAPL, indicating that 
endogenous ZAPL itself is not responsible for catalyzing this poly(ADP-
ribosylation). This result is as expected because ZAPL lacks the catalytic 
activity for poly(ADP-ribosylation) (Kleine et al., 2008). 
The experiment in Figure 3.8 suggested that the poly(ADP-ribosylated) 
PB2 and PA protein accumulate in the Z2 region of ZAPL. To verify this 
conclusion, we determined whether PB2 bound on Z2 fragment is poly(ADP-
ribosylated). Cells were transfected with PB2 and with or without Z2-1xFlag 
plasmid, followed by MG132 treatment. Cell extracts were immunoprecipitated 
with Flag-M2-beads to detected the presence of poly(ADP-ribosyalted) PB2. 
Figure 3.14B shows that poly(ADP-ribsyalted) PB2 was detected bound on 
the Z2 fragment of ZAPL, verifying poly(ADP-ribosylated) PB2 and PA are 
associated with the Z2 region of ZAPL. 
We next determined whether the poly(ADP-ribosylation) of PA and PB2 is 
involved in ZAPL-mediated proteasomal degradation. It was known that 
poly(ADP-ribosylation) on certain cytoplasmic proteins was increased by 
siRNA knockdown of cytoplasmic PARG proteins (Poly(ADP-ribosylation)  
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Figure 3.14 Poly(ADP-ribosylation) of PB2 is not catalyzed by ZAPL, but 
is involved for ZAPL-mediated degradation. (A) 293T cells were 
transfected with V5-Z1 ZAP fragment or control plasmid, followed by infection 
with a retrovirus expressing PB2 with 1xFlag tag and then MG132 treatment. 
An aliquot of the cell extracts was immunoblotted with the indicated Abs as 
input. Cell extracts were immunoprecipitated with Flag-antibody-conjugated 
beads and the immunoprecipitates were analyzed by immunoblots probed 
with an Ab against pADPr. (B) 293T cells were transfected with PB2 and with 
or without 1xFlag tagged Z2 plasmid, followed by MG132 treatment. Aliquots 
of the cell extracts were immunoblotted with the indicated Abs as input. After 
immunoprecipitation with Flag-M2-beads, the immunoprecipitates were 
immunoblotted with the indicated Abs. (C) 293T cells were transfected with 
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control siRNA or PARG-specific siRNA for 48 hours, followed by infection with 
a retrovirus expressing PB2 for 24 hours. Cell extracts were immunoblotted 
with the indicated Abs. 
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glycohydrolases) which is an enzyme to remove poly(ADP-ribose) 
modifications (Erdelyi et al., 2009; Leung et al., 2011). Cells were transfected 
with control siRNA or PARG-specific siRNA, followed by infection with a 
retrovirus expressing PB2. As shown in Figure 3.14C, knockdown of PARG 
significantly increased PB2 degradation, indicating that poly(ADP-ribosylation) 
of PB2 is involved in its degradation. Taken together, these results show that 
PB2 and PA are poly(ADP-ribosylated) and their poly(ADP-ribose) chains are 
likely associated with the ZAPL WWE domain, leading to the proteasomal 
degradation of PB2 and PA. 
3.3.7 PB1 binding to ZAPL leads to the dissociation of PA and PB2 from 
ZAPL, thereby protecting PA and PB2 from degradation 
    We have shown that PB1 binds to a region on ZAPL that is relatively 
close to the PB2 and PA binding site (Figure 3.8), and PB1 is not degraded by 
ZAPL, therefore we postulated that the interaction of PB1 with ZAPL might 
lead to the dissociation of PB2 and PA from ZAPL. To test this possibility, a 
protein-protein competition assay was performed. Cells were transfected with 
ZAPL and the indicated amounts of the PA or PB2, and PB1 plasmids, and 
then treated with MG132, a condition under which PB2 and PA are stabilized 
and remain bound to ZAPL. Cell extracts were immunoprecipitated with ZAPL, 
and detected the interaction with PA, PB2 or PB1 (Figure 3.15). In addition, 
we first determined the levels of PA and PB2 that saturated the amount of 
ZAPL produced, so that PB1 would be expected to bind predominantly to the 
same ZAPL molecules that bind PA and PB2. Under this conditions, the 
MG132-stablized PA and PB2 that was bound to ZAPL was found to 
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dissociate from ZAPL by the presence of increasing amount of PB1, 
concomitant with PB1 binding to ZAPL (Lane 3-5 in Figure 3.15A, B). 
Furthermore, the dissociation of PA and PB2 would be expected to protect 
them from ZAPL-mediated degradation. To test this prediction, we determined 
whether co-expression of PB1 can protect PA and PB2 from ZAPL-mediated 
degradation in the absence of MG132 treatment (Figure 3.16A). We found 
that the degradation of PA and PB2 in cells transfected with ZAPL was largely 
reversed by co-transfection with PB1. These results show that PB1 binding to 
ZAPL dissociates PA and PB2 from ZAPL, thereby protecting PA and PB2 
from degradation. 
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Figure 3.15 PB1 binding to ZAPL dissociates PA and PB2 from ZAPL. (A-
B) 293T cells were treated with MG132 or DMSO after transfection with ZAPL 
and the indicated amounts of the PA (B), PB2 (A), and PB1 plasmids. Cell 
extracts were immunoprecipitated with ZAPL Ab, and the immunoprecipitates 
and the cell extracts were immunoblotted with ZAPL Ab, and PA, PB2, or PB1 
Ab, as indicated. 
 
 
Figure 3.16 PB1 protects PA and PB2 from ZAPL-mediated degradation. 
293T cells were transfected with ZAPL, PB2, PA, PB1 plasmids where 
indicated, and cell extracts were immunoblotted with the indicated Abs. 
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3.4 Discussion 
    In the present study we identified a new antiviral activity of ZAPL and 
showed that this activity is directed against influenza A virus. The previously 
identified ZAPL antiviral activity is mediated by its N-terminal fingers which 
bind to the mRNAs of several viruses and promote the degradation of these 
mRNAs (Bick et al., 2003; Gao et al., 2002; Guo et al., 2004; Guo et al., 
2007a; Kerns et al., 2008; Muller et al., 2007; Zhu et al., 2011). In contrast, 
the newly identified ZAPL antiviral activity involves its C-terminal PARP 
domain, which binds the influenza A virus PB2 and PA polymerase proteins on 
separate ZAPL molecules. These two viral proteins are poly(ADP-ribosylated), 
presumably by PARP(s) other than ZAPL (Leung et al., 2011) which lacks this 
activity (Kleine et al., 2008). The ZAPL-associated, poly(ADP-ribosylated) PA 
and PB2 proteins are then ubiquitinated, followed by proteasomal degradation. 
This ZAPL mechanism explains why endogenous ZAPL inhibits influenza A 
virus replication, as we established by a siRNA knockdown experiment. 
The PB1 protein counteracts the newly identified ZAPL antiviral activity by 
binding to the WWE region adjacent to the PARP domain, causing PB2 and 
PA to dissociate from ZAPL and therefore escape degradation. This function 
of the PB1 protein explains why influenza A virus infection is only moderately 
inhibited (20-30-fold) by endogenous ZAPL, indicating that influenza A virus 
has partially won the battle against this newly identified ZAPL antiviral activity. 
ZAPL, which is located in the cytoplasm (Charron et al., 2013; Leung et al., 
2011), likely interacts with the PA, PB2 and PB1 proteins in the cytoplasm 
before they interact with each other and enter the nucleus to form tripartite 
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polymerase complex. Consistent with this cellular site of interaction, 
immunofluorescence of cells co-expressed with ZAPL and PA, PB2, or PB1 
plasmid verified that ZAPL interacts with PA, PB2 and PB1 in the cytoplasm. 
The situation in virus-infected cells is more complicated. For example, in 
infected cells cytoplasmic PB1 could potentially interact not only with ZAPL, 
but also with PA and DDX21 (Chen et al., 2014; Fodor and Smith, 2004), 
indicating that only some, but not all the PB1 in the cytoplasm would be 
available to counteract ZAPL. Because the binding of PB1 to ZAPL 
suppresses ZAPL antiviral activity, eliminating this PB1 binding would be 
expected to substantially increase the inhibition of virus replication, so that the 
PB1 interface with ZAPL is a potential target for antiviral development. 
Furthermore, since PB1 structure was solved recently (Pflug et al., 2014; 
Reich et al., 2014), further study is needed to determine whether it is feasible 
to generate a PB1 mutant virus whose primary defect is in ZAPL binding. 
Because PB1 was shown to tightly interact with PA and PB2 proteins, it may 
not be feasible to determine such PB1 mutant that does not interfere with 
interaction with PA and PB2. 
By purification of CPSF30-NS1A complexes from virus infected cells, we 
have identified not only DDX21 (Chen et al., 2014), but also ZAPL as 
restriction factors against influenza virus replication. We further determined 
the mechanism how influenza virus counteracts these antiviral activities. ZAPL 
likely through binding to PB1 (and NP) associates with CPSF30-NS1A 
complexes, which is presumably the end result of the battle between influenza 
A virus and the newly identified ZAPL antiviral activity. However, we do not 
know the consequence of such association of ZAPL in the CPSF30-NS1A 
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complexes to the virus replication. 
ZAPL (PARP 13.1) also has an important cellular function as a PARP 
protein. It interacts with Argonaute proteins (as well as several other cellular 
RNA-binding proteins), and both the Argonaute protein and ZAPL itself are 
poly(ADP-ribosylated) presumably by other cytoplasmic PARP proteins 
(Leung et al., 2011). Poly(ADP-ribosylation) of Argonaute increases during 
stress, leading to the relief of microRNA-mediated silencing of translation and 
hence to uninhibited translation of cellular mRNAs that are regulated by 
microRNAs. It is not known whether this cellular function is compromised by 
the utilization of ZAPL for antiviral activity in influenza A virus-infected cells. In 
other studies, it was shown that poly(ADP-ribosylated) proteins associated 
with a different PARP-containing protein, tankyrase, are ubiquitinated by an 
E3 ligase (i.e. RNF146) which recognizes poly(ADP-ribose) chains via its 
WWE domain and also binds to specific domains in tankyrase itself (DaRosa 
et al., 2014; Guettler et al., 2011). Hence, tankyrase is an essential scaffold 
for the E3 ligase that ubiquitinates the poly(ADP-ribosylated) protein bound to 
tankyrase. 
These previous studies, coupled with the results we report here, provide 
a working model for the ZAPL-dependent degradation of PB2 and PA (Figure 
3.17). We showed that PB2 and PA are targeted by ZAPL PARP domain, and 
that after these two viral proteins are poly(ADP-ribosylated) they accumulate 
in the region containing WWE and PARP domain, most likely because the 
WWE domain specifically binds poly(ADP-ribose) chains (DaRosa et al., 2014; 
Wang et al., 2012). It is likely that this accumulation would be blocked by the  
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Figure 3.17 Working model for the ZAPL-dependent degradation of PB2 
and PA. The model for PA degradation is the same as that shown here for 
PB2. The mechanism by which PB1 counters ZAPL-dependent degradation of 
PB2 is also shown. The model is described in the Discussion. 
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binding of the PB1 protein to the WWE region. Based on the tankyrase model, 
we proposed that poly(ADP-ribosylated) PA and PB2 are ubiquitinated by an 
E3 ligase that recognizes not only the poly(ADP-ribose) chains on PA and 
PB2 but also the ZAPL scaffold, specifically regions of ZAPL that are N-
terminal to the WWE domain. It should be noted that in this mechanism ZAPL 
rather than the E3 ligase provides the WWE domain that binds poly(ADP-
ribose) chains, whereas in the tankyrase model the E3 ligase provides the 
WWE domain (DaRosa et al., 2014). Basically ZAPL via its PARP domain is 
responsible for selecting the substrate (PB2 or PA) and then serves as a 
platform for the modification of the substrate that is catalyzed by other 
molecules, namely, ubiquitination of poly(ADP-ribosylated) substrate by an E3 
ligase. 
3.5 Future directions 
    In the present study we proposed a working model for the new ZAPL 
antiviral activity against influenza A virus that we identified. To further support 
our proposed model, several experiments are proposed.  
First, to show the PA and PB2 proteins are targeted for proteasomal 
degradation by endogenous ZAPL in influenza A virus-infected cells, A549 
cells with or without siRNA knockdown of ZAPL will be infected with Ud virus 
at low MOI and a pulse-chase labeling experiment will be performed. Viral 
proteins will be radiolabeled for one hour with S35-cysteine and methionine, 
followed by incubation in tissue culture medium containing high levels of 
unlabeled cysteine and methionine for various time periods. We will measure 
the amount of radiolabeled PB2, PA, and PB1 as a control. Based on our 
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results, knockdown of endogenous ZAPL is expected to increase the PA and 
PB2 protein stability in virus infected cells, leading to enhanced virus 
replication. 
Second, I will identify the PARP proteins and E3 ligase that are 
responsible for poly(ADP-ribosylation) and ubiquitination of PB2 and PA, 
respectively. It was reported that ZAPL binds to PARP12 and PARP15 to 
perform poly(ADP-ribosylation) of cellular proteins that are bound to ZAPL 
(Leung et al., 2011). To determine whether PARP12 and PARP15 poly(ADP-
ribosylate) PA and PB2, PARP12 and PARP15 will be knocked down with 
siRNAs to determine the effect on PA and PB2 poly(ADP-ribosylation). For the 
identification of the E3 ligase, cells will be co-transfected with GST-ZAPL and 
Flag-PB2 and treated with MG132 to inhibit proteasomal degradation, and 
then ZAPL-PB2 protein complex will be purified by sequential GST and Flag 
selection, and sent to mass spectrometry analysis to identify the associated 
proteins including one or more E3 ligases that will be candidates for the E3 
ligase that ubiquitinates PB2 and PA. Mass spectrometry may also identify the 
PARP proteins that catalyze PB2 poly(ADP-ribosylation. It is likely that a 
stable complex containing ZAPL, PB2 and E3 ligase exists because in the 
RNF146-tankyrase model it was reported that the RNF146 E3 ligase forms a 
stable complex with tankarase, a PARP-containing protein, to ubiquitinate the 
poly(ADP-ribosylated) target protein (DaRosa et al., 2014). 
 It is possible that ZAPL might inhibit the interaction of NS1 with CPSF30, 
leading to the inhibition of virus replication. The effect of ZAPL association 
with NS1-CPSF30 complexes will be determined. As the first approach, ZAPL 
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will be knocked down with a siRNA and the interaction of NS1 with CPSF30 
will be determined.  
Second, ZAPL was shown to destabilize TRAILR4 transcripts to regulate 
TRAIL-mediated apoptosis in the absence of viral infection (Todorova et al., 
2014). The effect that knockdown of ZAPL leads to increased influenza A virus 
replication might be a result of reduced TRAIL-mediated apoptosis, which 
may favors virus replication. To test this possibility, cells will be transfected 
with siRNA to knockdown ZAPL and then infected with Ud virus, and then 
whether cells with or without knockdown of ZAPL are in different apoptotic 
status will be determined by measuring caspase-3 activity. 
ZAPL was reported to block microRNA function during stress, specifically 
the relief of microRNA-mediated silencing of translation and hence to 
uninhibited translation of cellular mRNAs that are regulated by microRNAs. 
This cellular function is probably compromised in influenza A virus-infected 
cells by the diversion of ZAPL molecules to carry out its antiviral function. 
(Leung et al., 2011). As a consequence microRNAs that repress the 
translation of the mRNAs encoded by interferon-stimulated genes (ISGs) 
would continue to repress the translation of these mRNAs, a function which 
would favor virus replication (Seo et al., 2013). We intend to test this 
possibility. 
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